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ABSTRACT 
Background: Retinitis pigmentosa (RP), an inherited degenerative ocular disease, is considered the most common type of 
retinal dystrophy. Abnormalities of the photoreceptors, particularly the rods, and of the retinal pigment epithelium, 
characterizes this disease. The abnormalities progress from the midperiphery to the central retina. We here reviewed the 
developments in RP genetics in the last decade, along with its clinical features and natural course. 
Methods: The present review focused on articles in English language published between January 2008 and February 2020, 
and deposited in PubMed/MEDLINE and Google Scholar databases. We searched for articles reporting on the clinical 
manifestations and genes related to both syndromic and non-syndromic RP. We screened and analyzed 139 articles, 
published in the last decade, referring to RP pathogenesis and identified, summarized, and highlighted the most significant 
genes implicated in either syndromic or non-syndromic RP pathogenesis, causing different clinical manifestations. 
Results: Recent literature revealed that approximately 80 genes are implicated in non-syndromic RP, and 30 genes in 
syndromic forms, such as Usher syndrome and Bardet‒Biedl syndrome (BBS). Moreover, it is estimated that 27 genes are 
implicated in autosomal dominant RP (adRP), 55 genes in autosomal recessive RP (arRP), and 6 genes in X-linked RP (xlRP), 
causing different RP phenotypes. Characteristically, RHO is the most prevalent adRP- and arRP-causing gene, and RPGR the 
most common xlRP-causing gene. Other important genes are PRPH2, RP1, CRX, RPE65, ABCA4, CRB1, and USH2Α. However, 
different phenotypes can also be caused by mutations in the same gene. 
Conclusions: The genetic heterogeneity of RP necessitates further study to map the exact mutations that cause more 
severe forms of RP, and to develop and use appropriate genetic or other effective therapies in future. 
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INTRODUCTION 
Retinitis pigmentosa (RP) is an inherited eye disease that 
manifests with various dystrophic and degenerative 
symptoms. It is thought to be the most common type of 
retinal dystrophy [1-5], and affects millions of individuals 
worldwide, including over 200,000 individuals in the USA 
[6, 7]. RP was first described by Van Trigt in 1853 (through 
an ophthalmoscope) and was recognized as a pathological 
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involves inflammation of the retina, RP refers to a 
hereditary condition without inflammation [8].  
Degeneration of rods and cones, and of the retinal 
pigment epithelium (RPE) is typical of RP disorders. The 
degeneration usually develops at the middle (50° to 90°) 
of the periphery of the retina and progresses towards the 
central region of the retina, frequently affecting the 
macula and fovea [2, 5-7]. Clinically, it differs from other 
retinal diseases, such as Leber congenital amaurosis (LCA), 
macular dystrophies (MD), and cone‒rod dystrophies 
(CRD), which are inherited retinal diseases (IRDs) that 
present at birth or early in postnatal life. It is also clinically 
distinct from non-progressive conditions, including 
achromatopsia and congenital stationary night blindness 
(CSNB) [7]. There are several other ocular conditions 
associated with RP. Refractive error or nystagmus may 
occur in early-onset RP, whereas macular hole, epiretinal 
membrane formation, and cystoid macular edema (CME) 
may be present in more than 50% of RP patients. In 
addition, posterior subcapsular cataracts are present in up 
to 45% of RP patients, secondary retinal vasoproliferative 
tumors, vitreous cysts in 6% of RP patients, and optic 
nerve head and fiber layer drusen in approximately 9% of 
RP patients [7].  
The present review sought to present the various types of 
RP, and the symptoms and retinal findings that appear 
progressively at each stage of the disease. In addition, we 
review the genetic heterogeneity of RP, referring to the 
genes most commonly implicated in different forms of the 
disease. We also analyze the clinical manifestations of 




We screened the PubMed/MEDLINE and Google Scholar 
databases for articles referring to clinical manifestations 
and genes related to both syndromic and non-syndromic 
RP. The present review focused on articles in the English 
language published between January 2008 and February 
2020. Keyword combinations of “retinitis pigmentosa,” 
“genetics,” “genes“, and “(non) syndromic“ were used.  
RESULTS 
In total, 105 articles were analyzed, with a focus on the 
most recent literature. Further bibliographic research on 
the reference list of these articles revealed another 34 
related articles that were also analyzed and included in 
the review. Based on the reviewed literature, this article 
focuses on the types and clinical manifestations of RP, and 
summarizes the key genes and disease-causing mutations 
associated with the pathogenesis of syndromic and non-
syndromic RP. Table 1 summarizes the genes reported to 
date as causes of Usher syndrome. Table 2 summarizes the 
genes reported to cause Bardet‒Biedl syndrome (BBS) in 
the current literature. Table 3 summarizes the genes 
reported to cause autosomal dominant (ad) RP in the 
current literature. Table 4 summarizes the genes reported 
to cause autosomal recessive (ar) RP in the current 
literature. Table 5 summarizes the overlap between genes 
causing RP and causing other IRDs, and Table 6 
summarizes all abbreviations used in the text. 
 
DISCUSSION 
TYPES OF RP 
Non-syndromic RP: Symptoms and retinal findings 
RP may occur alone without other clinical manifestations, 
and is then known as non-syndromic RP, or it may occur 
along with developmental abnormalities, neurosensory 
disorders, or various combined clinical phenotypes, and is 
then known as syndromic (or systemic) RP [9]. 
Approximately 70‒80% of all RP cases are non-syndromic. 
The worldwide prevalence of RP in patients without 
systemic manifestations is estimated to be 1 in 4000 [1-4, 
9, 10], although it ranges from 1:9000 to 1:750, depending 
on the geographic location [7]. For instance, it is estimated 
to be 1:3800 in China [1].  
Non-syndromic RP is inherited in an ad form (adRP; 20‒
40%), ar form (arRP; 30‒50%), or in an X-linked form (xlRP) 
(5‒15%) [1-4, 9, 11]. Non-Mendelian inheritance patterns 
accounts for only a minor proportion of cases. These 
include digenic, mitochondrial, and de novo mutations [3, 
4, 9, 11, 12]. In addition, approximately 30% of all non-
syndromic RP cases are sporadic, while most exhibit an 
apparently autosomal recessive inheritance [1, 3, 12]. 
However, these percentages vary among populations [3].  
XlRP appears to be the most severe form of RP, as it 
progresses more aggressively and is characterized by 
early-onset. Clinically, it is more severe in men than in 
women [10]. AdRP cases are characterized by the best 
long-term prognosis in terms of retaining central vision 
[7]. In a previous report, by the age of 20 years, 87% of 
patients with xlRP and 75% of patients with adRP had 
symptoms, whereas this proportion was only 61% for arRP 
and 64% with simplex cases. By the age of 30 years, all xlRP 
patients, 89% of adRP patients, 74% of arRP patients, and 
79% of simplex cases presented with symptoms [8]. 
Hence, adRP has been reported to have the best 
prognosis, whereas xlRP is the most aggressive form, and 
in xlRP all patients aged 50 years and older have a visual 
acuity worse than 20/200. In addition, intermediate 
severity is present in patients with arRP. However, other 
reports suggest that genetic subtypes do not affect central 
visual impairment [8]. 
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Syndromic RP 
Approximately 20‒30% of RP cases present with systemic 
manifestations. Syndromic RP appears in more than 30 
different syndromes. Overall 20‒40% of these cases are 
inherited in a recessive manner and 10‒20% appear in 
conjunction with Usher syndrome [9]. It is a major cause 
of combined deafness and blindness, and is responsible 
for approximately 50% of all cases with these symptoms. 
It affects 1:12,000 to 1:30,000 individuals in different 
populations and has a prevalence of 5‒6 per 100,000 
individuals in the USA and Northern Europe [12, 13].  
It is divided into three types. Type I, which is present at 
birth, is the most severe form, and is characterized by 
progressive hearing loss and is associated with vestibular 
ataxia. Type II, which is non-progressive, congenital, and 
mild to moderate in severity, presents with retinal 
degeneration in older age, but without vestibular 
dysfunction. Type III, which is progressive, with normal 
hearing present in youth and with gradual hearing loss 
during later years [9, 12, 13]. Mental and behavioral 
disorders, including schizophrenia-like psychosis, have 
also been reported in Usher patients [13]. There are 12‒
15 genes that can cause Usher’s syndrome, with different 
mutations causing each type, while some mutations may 
cause either RP without hearing loss or deafness without 
RP [9]. Genes implicated in type I Usher syndrome are 
MYO7A (USH1B; 11q13.5), CDH23 (USH1D; 10q22.1), 
PCDH15 (USH1F; 10q21.1), USH1C (USH1C; 11p15.1), 
USH1G (USH1G; 17q25.1), CIB2 (15q25.1), and CLRN1 
(3q25.1). Those involved in type II are USH2A (USH2A; 
1q41), GPR98 (USH2C; 5q14.3), and DFNB31 (USH2; 9q32). 
Genes involved in type III are HARS (USH3A; 5q31.3), and 
ABHD12 (2p11.21) [12, 14]. Table 1 summarizes the genes 
reported to date as causes of Usher syndrome. 
Bardet‒Biedl syndrome (BBS) is a syndrome that may 
involve syndromic RP. It is characterized by a fundus 
abnormality with early macular involvement, consisting of 
a non-typical pigmentary retinal dystrophy. BBS accounts 
for as many as 5–6% of RP cases [9]. The prognosis for 
affected children is poor, as legal blindness appears at the 
age of 15.5 years. Night blindness is also observed in the 
first decade. BBS is associated with kidney disease, 
polydactyly, obesity, renal dysfunction, hypogonadotropic 
hypogonadism (in male patients), genitourinary 
malformations (in female patients), cognitive impairment, 
and developmental delay. Mortality is frequently 
associated with renal disease, which is inherited in an 
autosomal recessive pattern, affecting 1:120,000 
Caucasians [12]. Mitochondrial diseases or degenerative 
cerebellar diseases may also be associated with BBS 
pathogenesis [6, 7]. These manifestations vary in BBS 
patients depending on the gene and the exact mutation 
implicated in BBS pathogenesis in each individual [7]. 
Twenty one genes have been identified in BBS, including 
BBS1 (11q13; implicated in 40% of BSS patients), BBS2 
(16q12.2; implicated in 20% of BSS patients), ARL6 (causing 
BBS3; 3q11.2), BBS4 (15q24.1; implicated in 3‒6% of BSS 
patients), BBS5 (2q31.1; implicated in 2% of BSS patients), 
MKKS (causing BBS6; 20p12.2), BBS7 (4q27), TTC8 (causing 
BBS8; 14q32.11), B1 (causing BBS9; 7p14.3), BBS10 
(12q21.2), TRIM32 (causing BBS11; 9q33.1), BBS12 (4q27), 
MKS1 (causing BBS13) (17q22), CEP290 (causing BBS14; 
12q21.32), BBIP1 (10q25.2), IFT27 (22q12.3), INPP5E 
(9q34.3), KCNJ13 (2q37.1), LZTFL1 (3p21.31), NPHP1 (2q13), 
and SDCCAG8 (1q43) [12, 14]. These genes cause 
approximately 70% of cases, and most of the mutations are 
associated with autosomal recessive patterns of inheritance 
[9]. Further BBS-associated genes are yet to be identified, as 
approximately 30% of BBS cases are not associated with any 
of the 21 genes reported to date [12]. Table 2 summarizes 
the genes reported to cause BBS in the current literature. 
Other clinically important syndromic forms of RP are 
Bassen‒Kornzweig syndrome (abetalipoproteinemia), 
Refsum’s disease (phytanic acid oxidase deficiency), and 
α-tocopherol transport protein deficiency (vitamin E 
deficiency) [9].  
 
Table 1. Genes Reported to Cause Usher Syndrome 
Gene Chromosome 
ABHD12 (Abhydrolase Domain Containing 12, Lysophospholipase) 2p11.21 [13] 
CDH23 (Cadherin Related 23) 10q22.1 [12, 13] 
CIB2  (Calcium And Integrin Binding Family Member 2) 15q25.1 [13] 
CLRN1  (Clarin 1) 3q25.1 [13] 
DFNB31  (Deafness, Autosomal Recessive 31) 9q32 [12, 13] 
GPR98  (G Protein-Coupled Receptor 98)  5q14.3 [12, 13] 
HARS  (Histidyl-TRNA Synthetase) 5q31.3 [13] 
MYO7A  (Myosin VIIA) 11q13.5 [12, 13] 
PCDH15  (Protocadherin Related 15) 10q21.1 [12, 13] 
USH1C  (USH1 Protein Network Component Harmonin) 11p15.1 [12, 13] 
USH1G  (USH1 Protein Network Component Sans) 17q25.1 [12, 13] 
USH2A  (Usherin) 1q41 [12, 13] 
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Symptoms of RP 
RP results in progressive vision loss and blindness [1]. The 
age of onset ranges from early childhood to mid-
adulthood [15]. Problems with dark adaptation often 
manifest during adolescence, while visual loss in the mid-
peripheral field is usually evident in the second and third 
decades of life. Despite this general rule, the age of onset 
varies among patients. Early onset RP usually progresses 
more rapidly. Some patients therefore develop visual loss 
by the age of 30, while others remain asymptomatic until 
the fifth decade of life [7]. The diagnosis of early-onset RP 
is based on the presence of mid-stage RP symptomatology 
after the age of 2 years. However, the diagnosis of late-
onset RP requires that the first symptoms of RP present in 
midlife or later [5, 6].  
Nevertheless, it is difficult to determine the age of RP 
onset accurately, because many patients, and particularly 
children, compensate for the loss of peripheral vision. In 
addition, the artificial illumination of nighttime 
environments tends to mask possible problems with dark 
adaptation [7]. In extreme cases, RP progresses rapidly 
over the course of two decades. At the other extreme, the 
disease may present with slow progression and may never 
lead to blindness [5]. RP is a very common cause of visual 
impairment in patients aged 30‒60 years, with higher 
parental consanguinity than other genetic diseases, such 
as Stargardt disease (STGD) and retinopathy of 
prematurity [16].    
Typically, RP is present during the first years of life. 
However, it may also appear in early adolescence or even 
later in life. Often, night blindness is not evident in young 
patients, and only becomes apparent between 12 and 18 
years old. There are also defects in the visual field in dim 
light, whereas minor defects appear in visual acuity, and 
color vision is normal. Thus, it is difficult to diagnose RP at 
an early stage, as symptoms may not yet have manifested, 
particularly in cases where there are no other family 
members affected with RP. Scotopic visual fields present 
scotomas and electroretinograms (ERGs) may be normal 
when RP has not yet progressed, while a decreased 
amplitude of the b-wave on ERG may be present in dark 
conditions [5-7]. 
In the mild stages, night blindness is obvious; there is 
loss in the peripheral visual field under photopic 
conditions, dyschromatopsia, particularly in terms of 
blue and yellow, and photophobia in diffuse light. 
Visual acuity is decreased, as macular involvement may 
also be present, or because of subcortical posterior 
cataract, which should be removed even in the 
presence of macular involvement. Atrophy of the retina 
is evident upon fundus examination at this stage, along 
with minute bone spicule-shaped pigment deposits at 
the middle periphery. The retinal vessels appear 
narrow, while the optic disc is rather pale. Scotopic ERG 
(rods), in most cases, cannot be recorded. ERG cone 
responses are markedly diminished. Mild peripheral 
scotomas are evident in visual field tests, frequently 




Table 2. Genes Reported to Cause Bardet-Biedl Syndrome 
Genes  Chromosome  
ARL6 (ADP Ribosylation Factor Like GTPase 6) 3q11.2 [12, 13] 
BBIP1 (BBSome Interacting Protein 1) 10q25.2 [13] 
BBS1 (Bardet-Biedl Syndrome 1) 11q13 [12, 13] 
BBS2 (Bardet-Biedl Syndrome 2) 16q12.2 [12, 13] 
BBS4 (Bardet-Biedl Syndrome 4) 15q24.1 [12, 13] 
BBS5 (Bardet-Biedl Syndrome 5) 2q31.1 [12, 13] 
BBS7 (Bardet-Biedl Syndrome 7) 4q27 [12, 13] 
BBS9 (Bardet-Biedl Syndrome 9) 7p14.3 [12, 13] 
BBS10 (Bardet-Biedl Syndrome 10) 12q21.2 [12, 13] 
BBS12 (Bardet-Biedl Syndrome 12) 4q27 [12, 13] 
CEP290 (Centrosomal Protein 290) 12q21.32 [12, 13] 
IFT27 (Intraflagellar Transport 27) 22q12.3 [13] 
KCNJ13 (Potassium Inwardly Rectifying Channel Subfamily J Member 13) 2q37.1 [13] 
LZTFL1 (Leucine Zipper Transcription Factor Like 1) 3p21.31 [13] 
NPHP1 (Nephrocystin 1) 2q13 [13] 
MKKS (McKusick-Kaufman Syndrome)  20p12.2 [12, 13] 
MKS1 (MKS Transition Zone Complex Subunit 1) 17q22 [12, 13] 
TRIM32 (Tripartite Motif Containing 32)  9q33.1 [12, 13] 
TTC8 (Tetratricopeptide Repeat Domain 8) 14q32.11 [12, 13] 
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The end stage of RP is characterized by the inability of 
RP patients to move autonomously because of 
peripheral vision loss and classic tunnel vision. Reading 
is difficult or impossible, photophobia is severe, ERG is 
unrecordable, and fundus examination reveals pigment 
deposits in the central retina, particularly the macula. 
The optic disc appears to have a waxy pallor, and the 
retinal vessels are thin. Chorioretinal atrophy is evident 
on fluorescein angiography, both at the periphery and 
at the foveomacular area [5-7].  
Hence, nyctalopia and difficulties in adapting to 
changes in brightness may be present in the early 
stages of RP [1, 5, 9]. This is considered to be the 
earliest symptom of RP [5] which, eventually, develops 
into “tunnel vision” (loss of peripheral vision) and, 
finally, legal or complete blindness [2, 5-7, 9]. The loss 
of photoreceptors in the outer retina, the rods that 
mediate vision at night and generally scotopic 
conditions, and the cones that mediate color vision and 
vision under generally photopic conditions may cause 
several visual symptoms. On the other hand, cells in the 
inner retina, including bipolar cells, amacrine cells, and 
ganglion cells, are affected later [9].  
Most frequently, nyctalopia usually starts in the first 
decade of life, while peripheral visual field defects are 
present in the second decade of life and, in most cases, 
by the fourth or fifth decade of life, visual acuity is 
completely lost. Nevertheless, the course of RP in 
female carriers is characterized by variable clinical 
symptoms, and visual impairment usually appears in 
early middle age [10]. Anatomical defects of the central 
retina may manifest early during the progression of the 
disease. However, the central retina and function of the 
macula are relatively free until the late stages of the 
disease. Eventually, cone degeneration causes poor 
visual acuity until the fourth decade of life, although 
most patients retain the ability to perceive light. This is 
associated with residual macular function [7].  
As already mentioned, another characteristic feature of 
RP is the progressive loss of the visual field, presenting 
with bilateral symmetry and beginning with scotomas in 
the mid-peripheral areas. These isolated scotomas 
gradually coalesce into an annular scotoma that extends 
both in the outward and inward directions. In addition, 
progression of concentric visual field loss, which follows 
an arcuate pattern and proceeds in the superior to inferior 
direction of the retina, has been reported [7, 9].  
Another common but often-neglected symptom of RP is 
photopsia. It can occur early in RP progression, but it may 
be highly disturbing in advanced RP. Photopsia may result 
from the absence of afferent nerve impulses due to 
photoreceptor degeneration or may be the result of 
spontaneous self-signaling due to inner retinal remodeling 
[5, 7].  
In addition, other symptoms that characterize RP patients 
are photophobia [5, 7], myopia, and hyperopia. Both 
myopia and hyperopia, particularly high forms, are also 
more prevalent in patients with RP. Hyperopia among RP 
patients mostly appears with mutations in CRB1, NR2E3, 
or LRAT. In contrast, myopia is more related to Usher 
syndrome. It is also associated with the RBP3, ZNF408, and 
RP1 genetic subtypes in arRP and with the RP2 and RPGR 
genetic subtypes in xlRP [7].  
At the cellular level, RP is a progressive disability resulting 
from the loss of rods. In the beginning, it compromises 
night vision by affecting the mid-peripheral retina, which 
has abundant rod photoreceptors. Subsequently, it 
progresses into the central retina, eventually eliminating 
cones either directly due to the disease process or 
indirectly through rod death [6, 7]. Finally, the disease 
onset, progression, retinal appearance (i.e., rod versus 
cone involvement, involvement of the RPE and other 
types of retinal cells, such as bipolar cells), secondary 
symptoms (e.g., CME), and final visual outcome vary 
widely, even among blood relatives [1, 3, 6, 7].  
Retinal findings of RP 
Upon examination, the main retinal manifestations 
include bone-spicule formations and thinning of blood 
vessels, a waxy pallor of the optic nerve, and changes in 
structure. Shortening of the photoreceptor outer 
segments (OSs) imaged by optical coherence tomography 
(OCT), reduced visual fields, and reduced and/or abnormal 
ERG [1, 2, 6, 10, 11], such as the amplitude diminution of 
a- and b-waves are paraclinical manifestations of RP [5]. 
This indicates characteristic loss mostly of rod 
photoreceptor function in the early stages of RP [7]. OCT, 
visual field examination, and ERG are non-invasive 
procedures that are not time-consuming and can be easily 
performed, even in adolescents. In particular, OCT and 
full-field ERG (ffERG) provide objective and detailed 
information about central retinal structure and function. 
Such information contributes to both the detection and 
identification of the clinical phenotype of RP [17]. 
In the early stages, vascular thinning is minimal, bone-
spicule formations are, at most, sparse, and the optic disc 
is mostly normal in appearance; thus, a fundus 
examination may appear normal. In addition, some RP 
patients may have non-specific abnormalities, such as 
broadening of the foveal reflex, irregular reflexes from the 
internal limiting membrane, or whitish lesions. However, 
some patients develop dust-like pigmentation, while 
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others develop nummular hyperpigmentation, which may 
vary among patients, without reflecting the severity of the 
disease. Melanin pigment deposits are formed by RPE cells 
with bone-spicule pigmentation, which are detached from 
Bruch’s membrane after photoreceptor degeneration and 
intraretinal migration. Bone-spicule formations are most 
often evident in the rod-rich mid-periphery [5, 7].  
Vascular thinning in the retina of RP patients seems to be 
the result of photoreceptor loss, leading to reduced 
metabolic demand. An alternative explanation is that it is 
the result of a hyperoxic state of the inner retina, 
provoking loss of oxygen-consuming photoreceptors, 
leading to retinal vessel thinning and reduced blood flow. 
A third explanation suggests that vessel narrowing is 
caused by thickening of the extracellular matrix, where 
the vessels are embedded together with the RPE cells that 
have migrated [7].  
Moreover, vascular remodeling and subsequent vessel 
attenuation are attributed to the decreased metabolism 
of the inner retinal layers [7]. Other studies suggest that 
retinal atrophy is associated with a reduction in ocular 
blood flow [5, 7]. Thus, it remains unclear whether RP-
associated vascular changes are secondary to neuroretinal 
remodeling or whether they are of primary importance for 
RP development. Additionally, the vasoconstrictor 
endothelin-1 may be involved in RP development. Finally, 
the waxy pallor, which typically develops in the optic disc, 
is due to the glial cells situated either on the surface or 
inside the optic disc, causing enhanced light reflectance 
[7]. 
 
GENETIC ASPECTS OF RP PATHOGENESIS 
Genes associated with RP pathogenesis 
The term IRDs includes several different diseases, with 
more than 190 genes involved in some form of IRD [6, 18]. 
RP seems to be associated with dozens of different genetic 
defects [7]. Hence, at a genetic level, RP is thought to be 
complicated and heterogeneous [1, 2, 10], while it 
accounts for approximately half of IRD cases. Non-
syndromic RP has been associated with more than 80 
genes [3, 6, 7], whereas approximately 30 genes may 
cause syndromic RP, such as that seen in Usher syndrome 
and BBS [2].  
Genes that are associated with RP belong to several 
groups. These include genes encoding proteins that 
convert a photon into a neuronal signal, a procedure 
important for normal vision, including rhodopsin (RHO), 
PDE6A, and PDE6B, which encode proteins of the visual 
cycle that recycle the chromophore of rhodopsin. Other 
genes encode tetraspanins, are structural photoreceptor 
proteins; photoreceptor cell transcription factors that 
enhance the expression of photoreceptor genes, including 
NRL and CRX. Additionally, some genes are involved in the 
regulation of catabolic functions in the retina, 
mitochondrial genes that are involved in mitochondrial 
metabolism, and several other categories. Moreover, 
there are genes with unknown functions that contribute 
to the progress of RP, such as RP1, RP2, RP3 (RP GTPase 
regulator, RPGR), RP12 (CRB1), and RP14 (TULP1) [19]. 
Hence, most genes encode proteins that are vital for the 
neuroretina and/or RPE, or some underlying structure. 
Thus, depending on the gene mutation, impaired or 
disrupted pathways may be caused. The first gene to be 
identified in adRP is RHO. Subsequently, several new 
genes have been implicated in RP pathogenesis. Each of 
these is associated with a specific RP subtype, which, in 
turn, is characterized by typical progression, age of onset, 
symptomatology, and retinal appearance. Several genes, 
such as CWC27, IMPDH1, and CRX, are related to early-
onset RP, whereas others, such as HGSNAT, CRX, and RBP3 
are associated with late-onset RP [7].  
A great many mutations in these genes are implicated in 
RP pathogenesis. There are more than 3100 mutations in 
non-syndromic RP genes alone [2, 3, 6, 20]. Syndromic RP 
is equally heterogeneous [6] and represents 20-30% of RP 
cases [7]. . As mentioned above, mutations in 12–15 genes 
may be implicated in Usher syndrome pathogenesis and 
21 genes with BBS pathogenesis [14]. Another 1200 
pathogenic mutations have been implicated in these 
syndromes. Apart from the genetic heterogeneity that 
they entail, various overlapping diseases and symptoms 
may be caused by mutations in the same gene. At the 
same time, there is great variation in their clinical 
expression. This variability manifests itself even among 
patients presenting with the same mutation in the same 
gene [6]. Within each subtype, various factors play a 
crucial role, indicating that the RP phenotype may be 
affected by genetic and environmental factors [7]. 
To date, approximately 27 adRP, 55 arRP, and 6 xlRP genes 
have been identified in the Genecards and RetNet 
databases [1, 11, 14]. Some genes can cause both adRP 
and arRP, such as RHO, BEST1, NRL, IMPDH1, NR2E3, RP1, 
and RPE65 [1, 21], while others can cause both RP and 
macular degeneration (MD), such as ABCA4, PROM1, 
PRPH2, C8orf37, and PRPF31 [1]. In addition, some genes 
have been implicated in both RP and LCA (CRB1, RPE65, 
CRX, LRAT, IMPDH1, PRPH2, SPATA7, RDH12, and TULP1) 
and others in both RP and cone dystrophy (CD)/CRD (CRX, 
C8orf37, PRPH2, PROM1, ABCA4, CERKL, SEMA4A, and 
RPGR) [2, 6].   
The most prevalent genetic causes of adRP are RHO, which 
causes approximately 26% of cases, RP1, which causes 6% 
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of cases, and the gene for pre-mRNA processing factor 31, 
PRPF31, which causes 5% of adRP in the United States. In 
Europe, the prevalence is lower for mutations in RHO 
(16.5%) and higher for mutations in PRPF31 (6.7%) [17]. 
Other mutated genes associated with adRP are SPP2 
(2q37.1), BEST1 (11q12.3), CRX (19q13.32), OR2W3 
(1q44), HK1 (10q22.1), TOPORS (9p21.1), GUCA1B 
(6p21.1), NRL (14q11.2), NR2E3 (15q23), SEMA4A (1q22), 
FSCN2 (17q25.3), RHO (3q22.1), CA4 (17q23.2), PRPH2 
(RDS) (6p21.1), RPE65 (1p31.2), PRPF8 (17p13.3), ROM1 
(11q12.3), PRPF31 (19q13.42), IMPDH1 (7q32.1), KLHL7 
(7p15.3), RP1 (8q12.1), PRPF4 (9q32), PRPF3 (1q21.2), 
RDH12 (14q24.1), PRPF6 (20q13.33), RP9 (7p14.3), and 
SNRNP200 (2q11.2) [12, 20]. It is estimated that among 
different populations, 50–75% of RP cases are associated 
with adRP gene mutations [20]. However, some of these 
mutations, at a later time, may be proven to be 
nonpathogenic, whereas other novel mutations that have 
not yet been identified may be discovered [6]. Table 3 
summarizes the genes reported to cause adRP in the 
current literature. 
In contrast, there are approximately 55 genes implicated 
in arRP. The following cause up to 2‒5% of cases: RPE65 
(1p31.2), PDE6A (5q33.1), PDE6B (4p16.3), and RP25. 
Other genes implicated in arRP are ADIPOR1 (1q32.1), 
POMGNT1 (1p34.1), ZNF408 (11p11.2), NEUROD1 
(2q31.3), IFT172 (2p33.3), IFT140 (16p13.3), HGSNAT 
(8p11.21), RDH11 (14q24.1), DHX38 (16q22.2), KIZ 
(20p11.23), BEST1 (11q12.3), ABCA4 (1p22.1), ARL2BP 
(16p13.3), C2orf71 (2p23.2), C8Oorf37 (8q22.1), CERKL 
(2q31.3), CLRN1 (3q25.1), CNGA1 (4p12), CNGB1 (16q13), 
CRB1 (1q31.3), DHDDS (1p36.11), DHX38 (16q22.2), EMC1 
(1p36.13), EYS (6q12), FAM161A (2p15), GPR125 (4p15.2), 
IDH3B (20p13), IMPG2 (3q12.3), KIAA1549 (7q34), KIZ 
(20p11.23), LRAT (4q32.1), MAK (6p24.2), MERTK (2q13), 
MVK (12q24.11), NEK2 (1q32.3), NR2E3 (15q23), NRL 
(14q11.2), PDE6G (17q25.3), PRCD (17q25.1), PROM1 
(4p15.32), RBP3 (10q11.22), RGR (10q23.1), RHO (3q22.1), 
RLBP1 (15q26.1), RP1 (8q12.1), SAG (2q37.1), SLC7A14 
(3q26.2), SPATA7 (14q31.3), TTC8 (14q32.11), TULP1 
(6p21.31), USH2A (1q41), ZNF513 (2p23.3) [12, 14]. Table 
4 summarizes the genes reported to cause arRP in the 
current literature. 
Six gene loci, mapped to the X-chromosome, have been 
implicated in xlRP pathogenesis: RPGR (Xp11.4), RP2 
(Xp11.23), RP6 (Xp21.3-p21.2), OFD1-RP23 (Xp22.2), RP24 
(Xq26-q27), and RP34 (Xq28-qter), the product of at least 
two of which have been identified: RPGR or RP3 and the 
RP2 protein (RP2) [6, 18]. It seems that RPGR mutations 
are responsible for approximately 70‒90% of xlRP cases 
and more than 20% of all RP cases, while 6–20% of xlRP 
cases are caused by RP2 mutations. In particular, RPGR is 
thought to be one of the most significant RP genes as it 
impacts central vision and appears at a high incidence 
[18]. Although, 30‒60% of all xlRP cases are associated 
with the ORF15 region, only 20% of RP3 mutations are 
present in RPGR coding exons. Thus, more than 80% of 
clinical cases are associated with RPGR and RP2. Hence, 
gene therapy and small-molecule drugs may focus on 
these genes [12].  
Interestingly, although the RP genes are universal, new 
mutations appear at roughly the same rate worldwide, 
and there are differences in the prevalence among 
different populations. For example, RHO mutations are 
responsible for 30% of adRP cases in Americans of 
European origin, but only 10% of such cases in China. This 
is thought to be due to the absence of the Pro23His 
mutation in China. On the other hand, the prevalence of 
other gene mutations, such as that of mutations in RPGR, 
is roughly the same worldwide [20].  
Genetic diagnosis of RP 
The functions of many genes have been extensively 
studied, but there is partial overlap of the clinical 
phenotypes of a number of these. Thus, it is necessary to 
discover accurate genotype‒phenotype correlations. Two 
main methods have been used for genetic diagnosis of 
IRD. Either specific genotyping microarrays are used 
which, depending on the IRD form, detect 11‒70% of 
mutations, or Sanger sequencing is used for mutation 
screening [3]. 
Several methods have been used to detect disease-
causing mutations, such as deletion detection, linkage 
mapping, and subclone sequencing of RPGR ORF15 [20]. 
Given that a precise prognosis of the symptomatology and 
appropriate genetic counseling are necessary for the 
correct management of IRDs, the molecular diagnosis of 
the IRD is of paramount importance. Important 
information may be provided by the molecular 
characterization of IRD-affected patients for the potential 
use of gene therapy. In addition, the development of new 
technologies, such as next-generation sequencing (NGS), 
has enabled the analysis of dozens of genes. This 
technique provides an easier molecular diagnosis of IRD, 
as it is characterized by high sensitivity and efficiency 
despite the heterogeneous nature of IRDs. NGS is thought 
to be very accurate in screening gene mutations and 
hence may be used efficiently as a diagnostic tool [3]. 
Three advanced technologies are using NGS, each with 
advantages and disadvantages: targeted retinal-gene 
capture NGS, whole-exome NGS, and whole-genome NGS. 
However, the present limitations of the NGS methods curb 
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their ability to detect insertions, deletions, and variable-
length repetitive elements [20].  
As already mentioned, gene therapy may be used widely 
in future, based on efficient and accurate diagnosis of the 
disease and disease-causing mutations. However, RP 
management may also be based on new approaches for 
cell replacement. Transplantation of stem cells may 
provide better vision in patients with RP. In addition, stem 
cells could restore structures of the retina that are 
affected in these patients, particularly when used at the 
appropriate time and stage of the disease. Previous 
animal studies on the use of stem cells, which can 
differentiate into retinal cells and progressively develop 
features of new cells, have shown encouraging results. 
However, future studies must optimize these approaches 
for their use in humans [22].  
Oxidative stress may also be a causative factor of various 
retinopathies, including RP, as it may enhance the death 
of photoreceptor cells. On the other hand, in the early 
stages, increased intake of lutein, an important 
antioxidant, may provide satisfactory protection to the 
retina and the macula, particularly in predisposing 
individuals. This emphasizes the need for early diagnosis. 
Similar protection of the retina and photoreceptors has 
been attributed to anthocyanins [23].  
The aim of molecular studies is to facilitate accurate 
genetic testing in RP patients, to provide information for 
use in clinical care and counseling. Additionally, new 
treatments based on improved understanding of disease 
pathogenesis will be developed. However, to attain this 
target, close cooperation between retinal specialists, 
genetic counselors, molecular geneticists, and 
bioinformatics experts is needed [20]. 
The extremely high heterogeneity of RP has led to many 
attempts to analyze and map the genes that contribute to 
the appearance and progression of several types of RP [6, 
12, 14]. Below, some of the most important genes 
involved in adRP, arRP, xlRP, and digenic RP are discussed. 
SPECIFIC GENES INVOLVED IN RP PAHOGENESIS 
RHO 
RHO (RP4, Opsin-2) is located on chromosome 3q22.1 and 
encodes the rod-specific protein, rhodopsin, which 
belongs to the G protein-coupled receptor (GPCR) family 
[6, 11, 24, 25]. Rhodopsin is produced in the inner 
segment (IS) of rods and is transported to the outer 
segment (OS) of the rods. It is a visual pigment that 
mediates vision in dim light, and it begins the visual 
transduction cascade [11]. 
The protein is composed of 348 amino acids, with seven 
transmembrane domains, a luminal N terminus, and a 
cytoplasmic C-terminus. The activation of rhodopsin 
protein is controlled by the 11-cis-retinal attachment site 
(Lys296), which is found in the seventh transmembrane 
domain [11]. 
RHO is known as the “major” gene of adRP [2, 4, 6, 24, 25]. 
It is also defined as RP4 and is responsible for about 20‒
30% of all adRP cases. More than 150 mutations in RHO 
have been identified as causing RP. The first RP causative 
gene defect in RHO was p.P23H, which is implicated in 
approximately 12% of USA RP patients [11, 19].  
Additionally, mutations in this gene are responsible for 
arRP. However, only a few arRP-causing mutations have 
been identified in RHO [11, 19], which are also associated 
with adCSNB [2, 6]. The prevalence of RHO mutations in 
adRP has been estimated to range from 16% to 35% in 
Western populations. In the Israeli and Palestinian 
populations, RHO mutations are also a significant cause of 
adRP [26]. Disease-causing mutations have also been 
identified in Spanish [27], Iranian [28], Japanese 29, and 
Korean [30] families with adRP. In Swedish families, 
mutations in RHO are associated with phenotypic 
intrafamilial variability and more severe phenotypes in 
younger generations [17]. For arRP, RHO mutations have 
been identified most frequently in Chinese families, The 
p.P347L mutation is the most common RHO mutation in 
China and is also a significant RP-associated mutation 
worldwide [11]. 
Finally, as RHO is a major causative gene in adRP, many 
therapies targeting RHO have been attempted in 
experimental animals. Moreover, the use of gene-
corrected autologous induced pluripotent stem cells 
(iPSCs) has been suggested for treating adRP patients [11]. 
PRPH2/RDS and ROM1 
PRPH2 is located on chromosome 6p21.1. This gene is also 
known as retinal degeneration slow/RDS [27]. It contains 
three exons and encodes peripherin 2, an integral 
membrane glycoprotein of 39-kDa, which is composed of 
346 amino acid proteins [2, 6]. This protein contains one 
intradiscal domain (D2) and four transmembrane domains 
(M1–M4) [31]. ROM1, which encodes rod outer-
membrane protein 1, along with RDS, encodes structural 
proteins of the photoreceptors; hence, it is important for 
the development and function of rods and cones. These 
proteins form heterotetramers in rod OS discs. ROM1 and 
PRPH2 encode proteins of the tetraspanin superfamily, 
which include four-transmembrane-domain proteins [19].  
Tetraspanins, as a family, contribute to the development 
of several signaling pathways and are associated with 
many different molecules. However, the heterogeneity of 
symptomatology in RP patients with either PRPH2 or 
ROM1 mutations indicates that another interacting 
protein is probably involved. Prominin like-1 (PROM-1) is 
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probably responsible for these interactions. It is a five-
transmembrane-domain protein localized to rod OS discs. 
PROM1 is mutated in autosomal recessive retinal 
degeneration [19].  
PRPH2 is thought to be a significant causative gene of 
adRP and CRD [27, 32-34]. Disease-causing mutations in 
PRPH2 are related to both adRP and adMD [1, 6, 35]. 
PRPH2 may be responsible for adSTGD1-like phenotypes 
[36], whereas a few dominant adult onset vitelliform 
macular dystrophy (AVMD) patients also carry mutations 
in PRPH2 [2, 37, 38]. It may also be related to secondary 
defects in neighboring tissues, including the choroid and 
RPE [31]. Thus, mutations in PRPH2 may be a direct cause 
of RP [19]. Over 151 PRPH2 mutations have been 
identified, many of which have been confirmed to be 
pathogenic. However, PRPH2-associated disease 
phenotypes display substantial variability, even among 
blood relatives carrying the same mutation [31].   
Mutations in ROM1 are not clearly linked to monogenic 
adRP [31]. However, an uncommon form of RP is 
autosomal digenic RP, which involves heterozygous 
mutations in both ROM1 and PRPH2 [2, 6, 39]. However, 
cases have been reported where RP is caused by ROM1 
mutations in the absence of PRPH2 mutations, whereas 
PRPH2 mutations have also been reported in several 
macular pattern dystrophies [19]. The question that has 
been pursued is how different mutations give rise to 
differences in disease phenotypes [40-42], but as of yet, 
this remains unclear. Many of the genes associated with 
retinal disease can potentially modify PRPH2-associated 
phenotypes. Among them, ROM1 is the most widely 
explored gene, due to the existence of PRPH2/ROM1 
digenic RP and ROM1 interaction with PRPH2. However, 
other genes have also been implicated in modifying the 
PRPH2-associated MD phenotype, including ABCA4 [31].  
The prevalence of adRP-related PRPH2 mutations varies 
widely according to the populations studied, ranging from 
0% in Mexican populations to 10.3% in French populations 
[24, 43]. PRPH2 is the second most common cause of adRP 
after RHO, in the French population. Moreover, PRPH2 
mutations were found in 4.7% of a Belgian cohort. PRPH2 
mutations are associated with highly variable phenotypes. 
These include moderate and mild forms of adRP. Mild 
forms can, at times, be underdiagnosed [43]. Most PRPH2 
mutations are sequence variants. Aberrant mRNA splicing, 
problems in protein localization, and protein degradation 
are some of the mechanisms which may result in 
decreased PRPH2 protein expression in rod OS [24].  
PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, and SNRNP200  
PRPF3, PRPF4, PRPF6, PRPF8, and PRPF31 encode pre-RNA 
processing factors 3, 4,6, 8, and 31, respectively [2]. Of 
these, PRPF3, PRPF8, and PRPF31, together with 
SNRNP200, are the major causative genes of RP. Indeed, 
the U4/U6-U5 tri-snRNP complex is composed of PRPF3, 
PRPF8, PRPF31, and SNRNP200 and is a major component 
of the spliceosome that participates in mRNA splicing [4, 
27, 44, 45]. More specifically, SNRNP200 encodes helicase 
hBrr2, a 200-KDa protein. Helicase hBrr2, together with 
several other RNA helicases, mediates the structural 
rearrangement of the spliceosome, permitting the 
unwinding of the U4/U6 snRNP duplex, and activating the 
catalytic properties of the spliceosome complex [4]. Both 
heterozygous and homozygous variants of this gene cause 
RP [46]. Approximately 38% of adRP patients showed 
mutations mainly in SNRNP200 and PRPF8 [4]. PRPF4 and 
PRPF6 mutations also cause adRP, albeit less frequently. 
All tissues in all eukaryotes express PRPF4 and PRPF6 [2]. 
PRPF4 encodes HPrp4, which is essential for continuous 
splicing. It has been reported that this gene co-segregates 
with the adRP disease phenotype in a Chinese family [47]. 
PRPF31 is located on 19q13.42 [2]. It is composed of 14 
exons and encodes a 499-amino acid protein that is 
implicated in spliceosome function. It binds to U4 small 
nuclear ribonucleoprotein (snRNP) in U4/U6 di-snRNP and 
contributes to the development of a connection between 
U5 and U4/U6 di-snRNP. PRPF31 is a common causative 
gene of adRP, after RHO and PRPH2, with over 40 RP-
causing mutations identified to date [48]. Furthermore, 
PRPF31 mutations have been reported to cause both RP 
and MD [1]. According to study on affected family with 
adRP in a large Chinese family, the age of RP patients 
ranged from 22 to 71 years, although the onset of night 
blindness extended from infancy to the fourth year of life 
[48].  
The phenotype of PRPF31 disease-causing mutations is 
highly heterogeneous, with extreme inter- and intra-
familial variability [17, 34]. Although these mutations 
cause adRP, they are non-penetrant, and several 
mutations are present without clinical manifestation [48-
50]. As a result, a few carriers of these mutations are blind, 
whereas others are asymptomatic [51]. Genetic modifiers 
are a potential cause of phenotypic variability. CNOT3 
encodes a protein of the CCR4-NOT complex, which is a 
conserved multiprotein structure that regulates gene 
expression. It is also a modifier in PRPF31-associated 
adRP, which explains the incomplete penetrance 
observed in families segregating these mutations [17].  
In adRP, the prevalence rate of PRPF31 mutations in 
different populations varies from 1% to 8% [52]. In the 
United States, this frequency is approximately 5%. In 
Europe, the prevalence is higher (6.7%) than in the 
American population. PRPF31 mutations have also been 
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reported in a Swedish population [17]. The prevalence of 
PRPF31 mutations in the Spanish population is estimated 
to be 7.6%, which is similar to that found in a French 
population (6.7%) [53]. However, these mutations are 
extremely rare in Asian population-based databases [29]. 
The prevalence of mutations in 
PRPF8, PRPF31 and SNRNP200, is high (19.8%) in the 
Belgian population. Mutations in PRPF31 have a 
prevalence of 10.5% ( 53% of the 19.8%). Together, 
mutations in PRPF8, PRPF31, and SNRNP200 are the major 
causative genes of adRP in the Belgian population [24]. 
In addition, PRPF3 (RP 18, SNRNP90) contains the three 
main mutations associated with ethnic variability in RP. 
The mutation T494M, the most frequent substitution in 
this gene, is a common causative mutation in adRP. 
T494M has been detected in American, Danish, English, 
Spanish, Swiss, Korean, and Japanese adRP families. P493S 
was identified in sporadic RP cases from Germany or the 
UK, as well as in a Caucasian adRP family in the USA. 
A489D has been referred to as an adRP family in Spain. On 
the other hand, PRPF3 mutations are rare in Chinese adRP 
patients [44]. 
RP1 
RP1 is located on 8q12 chromosome and contains four 
exons. It encodes a 2,156 amino acid protein, oxygen-
regulated protein 1 [21, 54, 55]. It is localized at the 
connecting cilia of rods and cones [55] and contributes to 
photoreceptor development, organization of 
photoreceptor OSs, and regulation of photoreceptor 
microtubules [54, 55]. Disease-causing mutations in this 
gene may cause both adRP and arRP [1, 3, 15, 24, 56], 
often associated with a relatively good prognosis [54]. In 
1999, it was thought to be an adRP-causing gene, but later 
arRP cases were associated with RP1 mutations. According 
to the estimate, disease-causing mutations in this gene 
account for 5% and 1% of adRP and arRP cases, 
respectively [55]. In addition to adRP and arRP, some 
studies have provided evidence that arCRD and arMD are 
also RP1-associated phenotypes [57].  
To date, over 150 disease-causing mutations have been 
detected in RP1, most of which are truncation variants. 
However, the pathway responsible for the 
dominant/recessive mutation effect remains unknown. It 
has been reported that deleterious effects of the 
truncated RP1 protein, caused by RP1 nonsense 
mutations, are mostly implicated in the development of 
retinal degeneration. In addition, it has been proposed 
that there are four distinct categories of truncation 
mutations in RP1 that affect the progression of RP 
differently [55]. 
Incomplete penetrance and variable expressivity have 
been observed in individuals carrying RP1 mutations, 
resulting in phenotypic variability, including the age of 
onset, abnormalities of the central and mid-peripheral 
retina, visual acuity and visual fields, and ERG findings. RP 
patients with homozygous or heterozygous RP1 mutations 
may develop arRP, which progresses in childhood, 
presenting with night blindness and progressive loss of 
visual acuity until the twentieth year of life. However, RP1 
mutation carriers mostly appear asymptomatic, whereas 
an increased risk of hypertriglyceridemia has been 
reported in homozygous carriers of p.N985Y [54].  
A nonsense mutation at codon 677 (p.R677) was one of 
the first analyzed RP1 mutations, which was estimated to 
be present in approximately 3% of adRP patients in North 
America [21]. Disease-causing mutations have also been 
identified in Iranian [28], Japanese [29] Korean [30], and 
Spanish families [27] with adRP, whereas disease-causing 
mutations were also identified in Spanish patients with 
arRP [55]. 
CRX 
CRX is localized on chromosome 19q13.33. It contains four 
exons and encodes a protein of 299 amino acids that is a 
homeodomain transcription factor [2, 6, 58]. CRX and NRL 
are photoreceptor cell transcription factors that control 
the expression of photoreceptor cell-specific genes, and 
both are known be mutated in the RP. Those mutations 
may prevent the development of rods and cones, and may 
cause degeneration of these cells over time [19]. 
Mutations in CRX can also lead to recessive, dominant, 
and de novo LCA, adCRD [2, 6, 19], and adRP [33, 35, 58]. 
ArRP-causing mutations in CRX have been reported in 
Japanese and other populations [29]. The phenotype of 
CRX mutations is heterogeneous, and incomplete 
penetrance of the mutations may be related to the 
influence of other genes [59, 60].  
CRX is also a common CRD-causative gene [32, 33, 60], and 
missense changes are most frequently found in adRP-
associated genes [27]. CRX mutations, like GUCY2D, AIPL1, 
and RPGRIP1 mutations result in poor visual acuity, 
starting within the first year of life [61]. In addition, CRX 
mutations associated with LCA often involve hyperopia 
[7]. 
RPE65  
RPE65 is located on 1p31.2, and encodes a 65-kDa retinol 
isomerase called RPE-specific protein that contributes to 
the visual cycle by renewing 11-cis retinal from all-trans 
retinol [2, 6, 62]. It is a member of the carotenoid cleavage 
oxygenase (CCO) enzyme family [61, 63, 64]. 
More than 100 mutations in RPE65 have been associated 
with arLCA [2, 6, 35, 62, 65, 66], RP [6, 35, 62, 65], and CRD 
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[67]. Additionally, a potential association with AVMD has 
been described [64]. More specifically, RPE65 mutations 
can cause both adRP and arRP [1, 6], but most mutations 
are associated with arRP [62]. 
RPE65-associated adRP also affects the choroid [63]. 
RPE65 mutations cause severe retinal dystrophies, mainly 
due to protein dysfunction and recessive inheritance. The 
c.1430A>G:p.Asp477Gly (D477G) mutation is the only 
known exception to this rule to date, as it is the cause of 
delayed-onset adRP and also affects the choroid and the 
macula [62]. Various phenotypes are present in D477G 
mutation carriers, including differences in the age of 
disease onset and disease severity, while most of them 
initially present with central visual impairment. They differ 
from typical RP patients, who present with progressive 
visual field loss starting from the mid-region and 
progressing to the far periphery [63, 64]. 
Patients with disease-causing mutations in RPE65 present 
early-onset degeneration, keratoconus, nystagmus, white 
dot deposits, and clumped pigment in advanced disease 
[68]. Severe visual impairment and night blindness are 
observed during infancy, and photophobia is observed 
during childhood [69]. High hyperopia is an additional 
common feature [67]. RPE65 mutations are also 
responsible for progressive visual impairment in older 
individuals. In addition, the appearance of 
symptomatology after infancy has been associated with 
better prognosis [61]. 
The highest prevalence of RPE65 variants is encountered 
in Caucasian populations, while high frequencies (16.5%) 
of RPE65 variants have been reported in the Indian 
population [70]. RPE65 mutations are responsible for 
approximately 16% of LCA cases, although it seems that 
this gene is not involved in Chinese LCA cases [67, 71]. On 
the other hand, adRP cases caused by RPE65 have been 
identified among Irish families, and is thought to reflect an 
Irish founder mutation [62, 64]. 
ABCA4  
ABCA4 consists of 50 exons and is located on chromosome 
1p13 [72]. The encoded protein is an ATP-binding cassette 
(ABC) transporter protein localized to the rims of rod and 
cone discs [6, 72-75]. The main function of the ABCA4 
protein is to transfer both N-retinylidene-
phosphatidylethanolamine and 
phosphatidylethanolamine from OS disc membranes of 
photoreceptors to the cytoplasmic leaflet during 
phototransduction. Thus, ABCA4 eliminates potentially 
toxic retinoid compounds from photoreceptors [72, 74, 
75]. 
At present, more than 800 mutations have been linked to 
ABCA4-associated phenotypes. ABCA4 mutations may be 
simple single-base substitutions or may be as extensive as 
the deletion of a few exons. However, most are missense 
mutations [72]. The severity of the retinal dystrophy 
phenotype may be related to the degree of mutation 
pathogenicity, which depends on their localization in 
various regulatory regions of the gene and the effect of 
the mutation on the amino acid composition of the 
protein molecule [76]. 
ABCA4 mutations are heterogeneous and are the most 
common cause of central retinal dystrophies [30, 33]. 
They can cause autosomal recessive Stargardt disease 
(arSTGD1), CD, CRD, and arRP [75-79]. In fact, ABCA4 is the 
major causative gene of STGD [36], and are commonly 
responsible for arCRD. ABCA4 has been reported as a 
major contributing gene to arCRD, whereas other known 
arCRD-related genes, including  PROM1, accounts for only 
a minor fraction of the reported cases [80].  
Some studies have also indicated that ABCA4 mutations 
are associated with atypical Usher syndrome [3, 81]. The 
most severe arRP phenotype involves injury to both the 
rods and cones. To date, 27 missense/nonsense 
mutations, nine splicing mutations, four deletions, and a 
complex rearrangement are thought to be responsible for 
homozygous or compound heterozygous arRP [82].  
Additionally, disease-causing mutations in ABCA4 are 
extremely heterogeneous with respect to ethnicity. In 
European patients, the p.G1961E mutation is prevalent at 
a frequency of 20.5%. On the other hand, p.A1773V and 
p.G818E are present in 17% and 15% of Mexican patients, 
respectively [77]. Among Thai patients, ABCA4 mutations 
are mainly responsible for the RP phenotype [6], whereas 
they are very rare in Chinese and Polish patients with 
arCRD [73, 83]. However, their frequency ranges from 
16.13% to 65% in European and American patients [73]. 
Electrophysiology contributes significantly to the 
diagnosis and follow-up of ABCA4-associated retinal 
disorders. Different phenotypeswere identified using 
different ERG patterns. In STGD, multifocal ERG (mERG) is 
typically attenuated with ffERG remaining normal or 
slightly affected. In CRD, mERG is always significantly 
attenuated, as are the cone responses in ffERG. ArRP is 
associated with an initial attenuation of the ffERG rod 
response, followed by reduced cone responses [84, 85].  
CRB1  
CRB1 encodes two proteins (1,376 and 1,406 amino acids 
long). It contains 12 exons and 11 introns and is located on 
1q31.3 [6, 86], The CRB1 protein is an extracellular signal 
protein. CRB1 includes three laminin A globular (AG)-like, 
a C-type lectin (CTL), and 19 epidermal growth factor 
(EGF)-like domains, and is extremely important for the 
formation and function of the retina [40, 86-88].  
  
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
242 RECENT DEVELOPMENTS IN RETINITIS PIGMENTOSA GENETICS 
To date, more than 200 CRB1 mutations implicated in arRP 
pathogenesis have been identified [40]. Among patients 
with RP attributable to CRB1 mutations, severe forms of 
retinal degeneration, such as LCA, appear in patients with 
null mutations in both alleles, including nonsense and 
frameshift mutations, whereas less aggressive forms, such 
as RP, are produced by heterozygous missense mutations 
[88, 89]. CRB1 mutations that lead to RP are associated 
with night blindness, followed by progressive peripheral 
vision loss, rod and cone degeneration, and rarely 
associated with complete blindness [88]. Disease-causing 
mutations in CRB1 frequently cause hyperopia [7]. CRB1 
mutations are related to various phenotypes and retinal 
dystrophies, such as early-onset RP, LCA, and CRD, and 
central phenotypes, including MD and foveal retinoschisis 
[6, 33, 35, 40, 61, 82, 86, 88, 90-92].  
In addition, CRB1 mutations are responsible for 3–9% of 
non-syndromic arRP cases [91]. Moreover, it was 
observed that 9‒15% of LCA cases have mutations in CRB1 
[93]. Recessive CRB1 mutations may also cause CRD with 
MD in childhood, with electronegative ERG [94]. These 
mutations are also responsible for adSTGD1-like 
phenotypes [36]. The variability of clinical manifestations 
in arRP patients with the same mutation in CRB1 indicates 
that other unknown factors may affect the pathogenesis 
[95]. 
CRB1 mutations frequently cause autosomal recessive 
retinal degeneration of early-onset in individuals from 
Israel, Palestine, and Spain [40, 89]. CRB1 mutations have 
been reported in four Chinese families. CRB1 sporadic 
mutations have been reported in RP subjects at a 
frequency of 5.8% [40, 92]. The most common types of 
arRP-causing mutations in patients from Israel and 
Palestine are also localized in CRB1. Furthermore, they are 
also present in Thai families with non-syndromic RP [96]. 
CRB1 mutations are also the most frequent cause of LCA 
among German patients [97]. Moreover, the prevalence 
of CRB1 mutations in a Danish LCA cohort was estimated 
at 7% [70]. CRB1 mutations have also been reported in the 
Brazilian CRD population [86]. In addition, it has been 
reported that Tunisian families with RP present mutations 
in CRB1, which are characterized by preserved para-
arteriolar RPE [68].  
PROM1  
PROM1 is located at 4p15.32 [6, 39, 98] and consists of 27 
exons. It encodes prominin-1, a five-transmembrane-
domain glycoprotein [6, 39, 84, 98]. The gene contributes 
to the development of disk membranes and is localized at 
the OS base of rods and cones. Stem and progenitor cells 
of several systems, such as neural and hematopoietic cells, 
or epithelial, glial, and photoreceptor cells of various 
organs, express the protein [98].  
Thirty-five PROM1 mutations have been identified [39]. 
The different disease-causing mutations in PROM1 have 
been suggested to be related to a variety of retinal 
degenerative phenotypes, such as arRP with MD, 
adSTGD1-like MD, autosomal dominant bull’s-eye MD, 
and CRD [1, 84, 99]. It has been reported that each PROM1 
mutation is related to a different phenotype. Missense 
mutations are mostly related to adSTGD1-like or bull's-eye 
MD. On the other hand, diseases such as RP and severe 
CRD with MD and nyctalopia are caused by nonsense and 
frameshift mutations in this gene [39, 83, 100]. 
Moreover, PROM1 mutations are strongly related to 
adCRD or arCRD [30, 32, 33, 80, 98] and adSTGD1-like 
phenotypes [30, 34, 84, 101, 102] In addition, carriers of 
PROM1 mutations have clinical manifestations of adMD 
[99]. PROM1 mutations are associated with high myopia 
[100], while the first symptoms of RP patients with PROM1 
mutations are nyctalopia and loss of visual fields [98]. 
In Thai and Chinese families, mutations in PROM1 are 
often responsible for arRP [39, 96]. In addition, recessive 
PROM1 mutations have been implicated in a Spanish 
family presenting with severe RP accompanied by MD and 
myopia. In these cases, PROM1 dysfunction may cause 
retinal degeneration [100]. 
PDE6  
Mutations in the gene encoding cyclic guanosine 
monophosphate (cGMP) phosphodiesterase 6 (PDE6) are 
responsible for approximately 8% of arRP cases. Abnormal 
cGMP metabolism may affect the visual signaling 
pathway, resulting in the death of photoreceptors and 
retinal degeneration. Hence, the regulation of cGMP 
concentrations in rods and cones is thought to be vital. 
Dysfunction of PDE6 may lead to photoreceptor 
degeneration, although the mechanisms initiating rod 
photoreceptor death are unclear [14].  
The PDE6 complex (including its PDE6A, PDE6B, PDE6G 
subunits) is crucial for rod phototransduction. Little is 
known about the processes that induce rod 
photoreceptor death in RP; however, low PDE6 activity 
apparently results in rod‒cone devolution. All PDE6 
subunits are necessary for proper photoreceptor function. 
PDE6A and PDE6B mutations seem to, quite commonly, 
induce arRP and heterozygous carriers of mutations in 
PDE6 are thought to be at a significant risk of visual loss. 
In contrast, PDE6G mutations are likely to cause early-
onset arRP [14]. 
In particular, the PDE6B, located on 4p16.3, encodes the 
rod cGMP phosphodiesterase beta subunit. PDE6B 
mutations are related to arRP [6, 103, 104], and they have 
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been identified in specific ethnic groups [30, 68, 105]. In 
the Korean population and in Caucasian Jews, PDE6B 
mutations are an extremely common cause of arRP [30, 
105]. RP caused by PDE6B mutations is characterized by 
childhood onset, night blindness, and photophobia [79, 
103], Mutations in PDE6B are also responsible for adCSNB 
[6]. 
TULP1  
TULP1, located on 6p21.31, is expressed only by rods and 
cones, and encodes the 542-amino acid tubby-like protein 
1, a member of the homonymous protein family [6, 106, 
107]. It consists of 15 exons in a 15-kb region. Rhodopsin, 
which is synthesized in the ISs of rods, is transported by 
TULP1 to the OSs via the connecting cilium (CC) [107, 108]. 
TULP1 is one of nine genes that have been implicated in 
the pathogenesis of both RP and LCA (RPE65, CRB1, 
SPATA7, CRX, RDH12, LRAT, TULP1, IMPDH1, and PRPH2) 
[35]. Disease-causing mutations in TULP1 have been 
reported in juvenile-onset arRP, rod‒cone dystrophy 
(RCD), and arLCA, implicating this gene with retinal 
degeneration [6, 15, 35, 61, 106-108]. Mutations in this 
gene have also been reported in Thai families with arRP 
and arLCA [96].    
There is clinical and genetic overlap between (early-onset) 
arRP and LCA, and it is often very difficult to differentiate 
these two conditions [107]. Biallelic TULP1 variants are 
associated with nystagmus, progressive nyctalopia, 
myopia, abnormal ERG, normal visual acuity and visual 
field in the first decade of life, and abnormalities of the 
peripheral retina [106, 108, 109]. In particular, nystagmus 
appears to be an unstable clinical feature [109]. 
C8orf37  
C8orf37, a gene located on 8q22.1 [6], encodes a 207-
amino acid protein of approximately 23 kDa whose 
function has not been determined. The C8orf37 protein 
colocalizes with γ-tubulin in immunolocalization studies of 
the retina, which is a basal body marker at the CC of rods 
and cones [41]. Therefore, mutations in C8orf37 may 
hinder intracellular traffic and thus play a role in the 
pathophysiology of RP, CRD, and BBS [1, 15, 110]. 
C8orf37 mutations cause arRP and arCRD [6, 15, 110, 111]. 
However, C8orf37 mutations are implicated in the 
pathogenesis of some BBS (BBS21) cases [110]. The 
relationship between C8orf37 mutations and BBS (BBS21) 
suggests that C8orf37 mutation carriers should be under 
surveillance to prevent the potential development of BBS-
contributing morbidities, such as obesity, renal 
abnormalities, diabetes, and hypertension [110, 111].  
The phenotypic heterogeneity associated with C8orf37 
mutations is wide, and overlap between RP and CRD is 
common. Distinguishing between RP (nyctalopia and 
developing visual field constriction) and CRD 
(photophobia, loss of central vision) greatly depends on 
their early symptoms. Given the substantial phenotypic 
overlap at the early stages, it is difficult to make a 
differential diagnosis of these conditions in their most 
severe presentations [41]. 
C8orf37 is also reported to be a causative gene of arRP in 
Thai families [96]. In addition, C8orf37 mutations have 
been reported to cause RP in two families from Pakistan. 
However, they are thought to be a rare cause of retinal 
dystrophy in this population [41].  
RPGR 
RPGR, located on Xp11.4 [6, 112], RP2, and OFD1 are 
genes associated with xlRP [10, 113]. Mutations in RPGR 
are responsible for approximately 70–90% of xlRP cases 
and mutations in RP2 cause around 6–20% of xlRP cases 
[10, 114]. There are more than 10 alternatively spliced 
transcripts of RPGR, while RPGRconst and RPGRORF15 are 
the two major RPGR isoforms identified  [10, 114]. The 
phenotypic spectrum of RPGR mutations is highly 
heterogeneous [42]. Mutations in RPGRORF15 may provoke 
xlRP, X-linked MD (xlMD), X-linked CD (xlCD), and X-linked 
atrophic MD [6, 10, 33, 73, 112, 114]. Approximately 50–
60% of RPGR mutations are clustered in the ORF15 exon, 
indicating that it is a hotspot for mutations. Most of these 
mutations are frameshift mutations, because the purine-
rich structure of the ORF15 exon apparently promotes 
polymerase arrest and slipped-strand mispairing events. 
Truncated products of RPGRORF15 of different lengths, 
affecting RPGRORF15 glutamylation, are caused by 
frameshift mutations [10, 114]. In addition, impaired 
glutamylation of RPGRORF15 is triggered by TTLL5 disease 
mutations, causing retinal dystrophy. Hence, in the 
absence of RPGRORF15 glutamylation, patients with TTLL5 
mutations present with retinal pathology because these 
two genes are components of a common disease pathway 
[18]. 
A large deletion in RP2 and four frameshift RPGR 
mutations have been identified in five families from China 
affected by xlRP [10]. Mutations in these genes have also 
been detected in Jordanian families with this disease 
[113]. Furthermore, disease-causing mutations have been 
identified in Japanese and other populations [29]. 
Mutations in RPGR cause LCA and juvenile RP. However, 
cases have been reported where the disease course was 
benign, with good visual acuity at presentation, which 
remained fairly stable up to over 40 years of age [34]. 
Nyctalopia and vision decline are present in RP-affected 
males with RP2 mutations. Males present with a graver 
phenotype than carrier females, who show different 
degrees of severity of myopia. With RP3 mutations, males 
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present with more severe phenotypes, while carrier 
females have several different clinical manifestations, 
from asymptomatic to severe RP. In addition, most of the 
females present with reduced vision, but rarely progress 
to complete blindness [112].  
The genotypic spectrum of RPGR variants has also been 
associated with systemic manifestations. The 
identification of these features in males and the 
phenotype in carrier females allows confirmation of 
pathogenic variants [115]. In addition, blindness by the 
age of 40 years occurs in approximately 20% and 55% of 
RP and CD/CRD patients, respectively [116]. 
USH2Α  
USH2A is located on chromosome 1q41 [6]. It consists of 
72 exons and encodes usherin, a 5,202 amino acid protein. 
This protein is localized at the apical IS recess of rods and 
cones of mammals, corresponding to the periciliary ridge 
complex that appears in the rods and cones of amphibia 
[117].  
It is estimated that 10‒15% of arRP cases and 30–40% of 
Usher syndrome type 2 cases are associated with USH2A 
mutations [117]. Moreover, mutations in USH2A, RPGR, 
PRPF31, and EYS are implicated in 48% of RP cases with 
known mutations [34]. Because USH2A mutations may be 
responsible for non-syndromic RP and Usher syndrome, 
their presence in a family necessitates a hearing 
examination for these patients [3]. In addition, late-onset 
non-syndromic arRP may be associated with USH2A 
mutations [79]. 
Approximately 7% of RP cases in the USA  are associated 
with mutations in USH2A. In addition, USHA2 mutations 
causing arRP have a high prevalence and show phenotypic 
variations among Spanish RP patients [117]. 
Approximately 74‒90% of Usher syndrome 2 cases in 
Caucasians are related to USH2A, which is also thought to 
be a significant causative arRP gene. Among Japanese 
patients with arRP, the prevalence of these mutations is 
4%. However, the Japanese and Caucasian population 
profiles of these mutations differ [118]. In addition, EYS 
and USH2A are thought to be the major genes responsible 
for RP in Japan [29, 119]. Furthermore, there are specific 
USH2A mutations associated with RP, without hearing, 
loss among Chinese and Thai patients [96, 120]. Finally, 
USH2A seems to be important in the pathogenesis of the 
disease among Israeli IRD cohorts [81] and arRP Korean 
families [30]. 
RDH12  
RDH12 is located on 14q24.1, and encodes an NADPH-
dependent retinal reductase that is a member of the 
retinol dehydrogenase family. RDH12 plays a vital role in 
the conversion of all-trans retinal and 11-cis retinal to 
their respective retinols. The protein is expressed in the 
ISs of rods and cones and plays a vital role in the cyclic 
regeneration of the 11-cis retinal and cone opsins [2, 6, 
61]. 
RDH12 mutations, which account for 3–7% of all ar retinal 
dystrophy cases, are significant causative genes of LCA [2, 
6, 35, 61, 65, 90]. Over 60 RDH12 mutations have been 
reported, mainly in patients with LCA and in early-onset 
retinal dystrophy cases occurring in families with arRP. 
Based on this, RDH12 mutations may cause many severe 
forms of blindness [61].  
RP RDH12 mutations are commonly associated with 
juvenile RP [68]. Late-onset and mild adRP may be caused 
by heterozygous RDH12 mutations [61, 99]. Retina-wide 
disease, of early-onset, accompanied by abnormalities 
particularly in the central retina, may be caused by RDH12 
mutations. This disease, with less rod dysfunction, has 
many similarities to early-onset CRD [121].  
BEST1  
BEST1, which is localized on 11q12-13, consists of 11 
exons and encodes a protein named bestrophin-1 [2, 122]. 
It is expressed predominantly in RPE and is a Ca2+-
activated Cl- channel. It is an inhibitor of the intracellular 
voltage-dependent Ca2+ channel and HCO3- transporter 
[122, 123]. 
More than 300 BEST1 mutations have been identified. 
They cause bestrophinopathies, such as BEST vitelliform 
MD (BVMD) and autosomal recessive bestrophinopathy 
(arB). Patients with BVMD and arBs present with wide 
genetic and phenotypic variability [123]. 
Furthermore, BEST1 mutations are associated with adRP 
and arRP [1, 124], LCA [123], AVMD, and adSTGD1-like 
phenotypes [36]. BEST1 is considered to be the major 
causative gene of vitelliform MD (VMD), even though 
many of these patients have mutations in genes such as 
IMPG1/IMPG2, but not in BEST1 or PRPH2 [37].  
SPATA7  
SPATA7 is localized on chromosome 14q313 and encodes 
a spermatogenesis-associated protein 7 [6]. The SPATA7 
protein, as a ciliary protein, is located at the primary cilium 
of cells and at the CC of rods and cones [125].    
Mutations in SPATA7 lead to both arRP and arLCA [6, 35, 
90]. Furthermore, SPATA7 binds to the RP GTPase 
regulator interacting protein 1 (RPGRIP1), a CC protein 
that is related to LCA. The apoptosis of rods, which is 
caused by protein mislocalization, is probably implicated 
in the development of LCA and juvenile RP [125]. 
Patients with SPATA7 mutations show disc pallor, 
arteriolar thinning, and RPE mottling [90]. There are 
indications that SPATA7 mutations account for a 
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significant number of LCA cases in the Chinese population 
(4.6% of LCA patients) [125]. 
NR2E3  
NR2E3, located on 15q23, encodes the nuclear receptor 
subfamily 2 group E3 [2]. Two domains are included in 
NR2E3, the DNA-binding domain (DBD) and the ligand-
binding domain (LBD), at the N- and C-terminus end, 
respectively. These domains are the NR2E3 regions most 
commonly mutated [126]. 
Mutations in NR2E3 are responsible for arRP and 
dominant and recessive retinopathy. Other diseases, 
including recessive Goldmann–Favre syndrome and 
recessive enhanced S-cone syndrome (ESC), may also be 
caused [2, 19]. Mutations in this gene can also lead to 
adRP [1]. Diagnosis is complicated by the presentation of 
various clinical manifestations and the severity of retinal 
degeneration caused by these mutations. Patients with 
NR2E3 mutations may present with Goldmann‐Favre 
syndrome (GFS) features, typical ERG pattern of ESCs, or 
clumped pigmentary retinal degeneration [126]. In 
addition, RP disease-causing mutations in NR2E3 are 
frequently associated with hyperopia [7]. 
Significant pathogenic mutations have been reported in 
various populations, including Thai patients [96], Tunisian 
families [68], and Indian arRP cases [109]. 
TTC8  
TTC8, located on 14q32.11, encodes tetratricopeptide-
repeat-domain 8 and is associated with arRP and recessive 
BBS [6]. A premature stop codon located in exon 6 of the 
gene may be triggered by a frameshift mutation in the 
previous exon. The frameshift mutation in exon 5 also 
results in the production of TTC8 that lacks the normal 
tetratricopeptide-repeats 11 and 15. Nonsense and 
frameshift mutations may reduce translation of the 
encoded protein. As a result, compound heterozygous 
patients lack a functional TTC8 protein, a condition that 
results in the development of BBS type 8. TTC8  mutations 
are found in only 2.8% of all patients with BSS. More 
specifically, in Japan, one family each with BBS2, BBS5, 
and BBS7 homozygotes have been reported, along with a 
family with BBS10 compound heterozygotes. However, 
BBS patients with TTC8 mutations are extremely rare 
[127]. 
CEP290  
Heterozygous CEP290 mutations are associated with LCA, 
early-onset RP [89], and syndromic RP, as it is associated 
with BBS type 14 [14]. Mutations in this gene are 
responsible for LCA. The protein is localized in the CC of 
rods and cones and in the centromeres of diving cells. 
CEP290 mutations may cause a reduction in OS length and 
thickness of several retinal layers. Poor visual acuity and 
rod‒cone vision loss were observed in these patients 
[128]. Sequence analysis in a Danish LCA cohort indicated 
that CEP290 mutations were responsible for 
approximately 7% of the cases [70]. 
CERKL  
CERKL, located on 2q31.3 [6], encodes a ceramide-kinase-
like protein and is associated with arRP [3, 79] and CRD. 
Mutations in the gene may provoke bone-spicule 
pigmentation with white dots, RPE atrophy in the macular 
area, chorioretinal atrophy in the central retina, and 
decreased visual acuity [79].  
CNGA3  
CNGA3 encodes the functional components of the 
phototransduction cascade in cone photoreceptors [129]. 
Several CNGA3 mutations have been implicated in the 
pathogenesis of various diseases, including IRDs, and 
more specifically with autosomal recessive 
achromatopsia, complete or incomplete achromatopsia, 
CD or CRD, LCA, and RP [66, 130-133]. CNGA3 mutations 
have been identified in the Korean population [30] and in 
Israeli families [81] as a significant cause of IRDs. In 
addition, mutations in this gene seem to be significant 
among Chinese patients with CRD and achromatopsia. 
Hence, many cases of severe retinal dystrophies of early-
onset may be related to CNGA3 mutations [134].  
SLC7A14  
Disease-causing mutations in the SLC7A14 cationic 
transporter gene are responsible for arRP and LCA [135]. 
SLC7A14 is thought to be an important causative gene for 
RP in Japanese patients with arRP or sporadic RP. The 
frequency and pathogenicity of SLC7A14 mutations may 
differ in terms of ethnicity, and these mutations were 
unlikely in Japanese patients [136].  
MERTK  
MERTK, a member of the MER/AXL/TYRO3 receptor kinase 
family, is composed of 19 exons [137] and encodes a 999 
amino acid transmembrane protein [66, 137]. Several cells 
and tissues express this protein, including macrophages, 
RPE, prostate, lung, and kidney [137].  
Approximately 1% of autosomal recessive retinal 
dystrophy cases are associated with mutations in MERTK. 
Progressive retinal dystrophies with childhood onset and 
macular defects characterize these patients [137]. MERTK 
mutations cause approximately 2% of severe IRD cases, 
including RP and CRD [138]. All known mutations are loss-
of-function mutations [139]. Patients present with 
increased sensitivity to light and with dark adaptation 
problems [33]. Germline MERTK mutations related to arRP 
have been identified in the Chinese population [139]. 
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IMPDH1  
Inosine monophosphate dehydrogenase 1 is the protein 
product of IMPDH1, which is located on 7q32.1 [2, 6]. This 
protein is involved in purine or amino acid synthesis [2]. 
Disease-causing mutations in IMPDH1 lead to adLCA and 
adRP [2, 6, 7, 35].  
SEMA4A  
SEMA4A, located on 1q22 chromosome, encodes 
semaphorin 4A and is associated with adRP and adCRD [2, 
6]. SEMA4A mutations are one of the most common 
causes of CRD [32]. 
LRAT  
LRAT, located on 4q32.1 chromosome, encodes lecithin 
retinol acyltransferase, and mutations in this gene are 
responsible for both arRP and arLCA [6, 35]. In specific 
populations, such as the Danish population, LRAT is a 
significant causative gene of LCA [70]. Disease-causing 
mutations in LRAT frequently also cause hyperopia in RP 
patients [7]. Table 5 summarizes the overlap between 
genes causing RP and causing other IRDs, and Table 6 
summarizes all abbreviations used in the text. 
This review, in addition to its strengths, has several 
limitations. The present review focused on articles 
published in the last decade by using two of the known 
databases, PubMed and Google Scholar; however, other 
databases were not searched. It also focused most on 
important genes that are implicated in RP pathogenesis, 
while other rare pathogenic mutations in less significant 
genes were not included. The review is concisely referred 
to some types of management that may be developed and 
used in the future, including antioxidant ingredients, stem 
cells, and gene therapy, without emphasis. Future 
research should focus on the individual types of RP, and 
particularly the progression and clinical manifestations 
caused by specific variants in order to identify more 
pathogenic mutations from other less aggressive 
mutations. This may enhance the effort to achieve 
specialized management, such as promising gene therapy, 
for each disease-causing mutation. 
 
Table 3. Genes reported to cause autosomal dominant retinitis pigmentosa. 
GENE CHROMOSOME OTHER DISEASES 
BEST1 (Bestrophin 1) 11q12.3 Dominant Vitreoretinochoroidopathy [12, 32], Recessive Bestrophinopathy [12, 118, 
119], Recessive RP [12, 18], Dominant MD [32], Best type [12, 119] 
CRX (Cone-Rod Homeobox) 19q13.32 Recessive, Dominant and de novo LCA [2, 6], Dominant CRD [12, 18, 29] 
GUCA1B (Guanylate Cyclase Activator 1B) 6p21.1 Dominant MD [12, 18] 
IMPDH1 (Inosine Monophosphate 
Dehydrogenase 1) 
7q32.1 Dominant LCA [2, 6, 12, 18] 
KLHL7 (Kelch Like Family Member 7) 7p15.3 [12, 18] 
NRL (Neural Retina Leucine Zipper) 14q11.2 Recessive RP [12, 18] 
NR2E3 (Nuclear Receptor Subfamily 2 Group 
E Member 3) 
15q23 Recessive RP [12, 18], Recessive Goldmann–Favre Syndrome [12, 17, 18], Recessive 
ESC [2, 12, 17, 18] 
PRPF3 (Pre-MRNA Processing Factor 3) 1q21.2 [12, 18] 
PRPF6 (Pre-MRNA Processing Factor 6) 20q13.33 [18] 
PRPF8 (Pre-MRNA Processing Factor 8) 17p13.3 [12, 18] 
PRPF31 (Pre-MRNA Processing Factor 31) 19q13.42 [12, 18] 
PRPH2 (Peripherin 2) 6p21.1 Dominant AVMD [1, 6], Dominant CRD [6, 12, 18], Dominant Central Areolar 
Choroidal Dystrophy [1, 6, 12] 
RDH12 (Retinol Dehydrogenase 12) 14q24.1 Recessive LCA [2, 6, 12, 18] 
RHO (Rhodopsin) 3q22.1 Dominant CSNB [2, 6], Recessive RP [2, 6, 12, 18] 
RP1 (RP1 Axonemal Microtubule Associated) 8q12.1 Recessive RP [12, 18] 
RP9 (RP9 Pre-MRNA Splicing Factor) 7p14.3 [12, 18] 
RPE65 (Retinoid Isomerohydrolase RPE65) 1p31.2 Recessive RP [12, 18],  Recessive LCA [2, 6, 18] 
SEMA4A (Semaphorin 4A) 1q22 Dominant CRD [2, 6, 12, 18] 
SNRNP200 (Small Nuclear 
Ribonucleoprotein U5 Subunit 200) 
2q11.2 [12, 18] 
TOPORS (TOP1 Binding Arginine/Serine Rich 
Protein, E3 Ubiquitin Ligase) 
9p21.1 [12, 18] 
Abbreviations: RP, Retinitis Pigmentosa; MD, Macular Dystrophy; LCA, Leber Congenital Amaurosis; CRD, Cone–rod Dystrophy; ESC, Enhanced S-cone 
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Table 4. Genes reported to cause autosomal recessive retinitis pigmentosa. 
GENES CHROMOSOME OTHER DISEASES 
ABCA4  (ATP Binding Cassette Subfamily A Member 4) 1p22.1 Recessive MD [12], Recessive CRD [12, 13], Autosomal Recessive 
Stargardt Disease  [12, 13, 71] 
BEST1  (Bestrophin 1) 11q12.3 Dominant Vitreoretinochoroidopathy [12, 32], Recessive 
Bestrophinopathy [12, 119], Recessive RP [12], Dominant MD [12, 
13], Best type [12, 13, 32, 119] 
C8ORF37  (Chromosome 8 Open Reading Frame 37) 8q22.1 CRD [6, 13, 14] 
CERKL  (Ceramide Kinase Like) 2q31.3 CRD [12, 13, 75] 
CNGA3  (Cyclic Nucleotide Gated Channel Subunit Alpha 3) 2q11.2 CRD [12, 62] and Achromatopsia [12, 126] 
CRB1  (Crumbs Cell Polarity Complex Component 1) 1q31.3 Recessive LCA [12, 13] and CRD [12, 13, 89] 
EYS (Eyes Shut Homolog) 6q12 [12, 13] 
IMPG2 (Interphotoreceptor Matrix Proteoglycan 2)  [12, 13] 
LRAT (Lecithin Retinol Acyltransferase) 4q32.1 Recessive LCA [6, 12, 13, 31] 
MERTK (MER Proto-Oncogene, Tyrosine Kinase)  CRD [12, 13, 134] 
NR2E3 (Nuclear Receptor Subfamily 2 Group E Member 3) 15q23 Dominant RP [2, 12, 13], Recessive ESC [2, 12, 13, 17] 
NRL (Neural Retina Leucine Zipper) 14q11.2 Dominant RP [12, 13] 
PDE6A (Phosphodiesterase 6A)  [12, 13] 
PDE6B (Phosphodiesterase 6B) 4p16.3 Dominant CSNB [6, 12, 13] 
PDE6G (Phosphodiesterase 6G)  [12, 13] 
PROM1 (Prominin 1) 4p15.32 Recessive RP with Macular Degeneration [13], Autosomal 
Dominant and Recessive CRD [13, 26], STGD   [13, 26, 28] 
RDH12 (Retinol Dehydrogenase 12) 14q24.1 Autosomal Recessive LCA [2, 6, 13] 
RHO (Rhodopsin) 3q22.1 Dominant CSNB [2, 6, 11], Recessive RP [2, 12, 13] 
RP1 (RP1 Axonemal Microtubule Associated) 8q12.1 Dominant RP [12, 13] 
RPE65 (Retinoid Isomerohydrolase RPE65) 1p31.2 Recessive LCA [6, 12], Autosomal Dominant RP [12, 13] and CRD 
[2, 12, 63] 
SLC7A14 (Solute Carrier Family 7 Member 14) 3q26.2 LCA [13, 131] 
SPATA7 (Spermatogenesis Associated 7) 14q313 Autosomal Recessive LCA [6, 12, 13, 31] 
TTC8 (Tetratricopeptide Repeat Domain 8) 14q32.11 Recessive BBS [6, 12, 13] 
TULP1 (TUB Like Protein 1) 6q21.31 Recessive LCA [6, 12, 13, 31] 
USH2A (Usherin) 1q41 Recessive Usher Syndrome [12, 13, 113] 
Abbreviations:  MD, Macular Dystrophy; CRD, Cone‒Rod Dystrophy; RP, Retinitis Pigmentosa; LCA, Leber Congetinal Amaurosis; ESC, Enhanced S-cone 
Syndrome; CSNB, Congenital Stationary Night Blindness; BBS, Bardet‒Biedl syndrome. 
 
 
Table 5: Overlap between genes causing retinitis pigmentosa and those causing other inherited retinal diseases. 
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CSNB [2, 6]          X   X          
AVMD [2, 36-38, 64]  X          X    X       
Achromatopsia [66, 130-133]     X            X      
LCA  [2, 6, 19, 34, 35, 61, 65, 66, 90, 93, 135]      X X X X     X  X X  X X X  
Stargardt Disease [1, 6, 36, 63, 64, 75-79, 84, 
99, 130] 
X X   X X     X X    X      X 
CRD [1, 2, 6, 15, 19, 27, 32-35, 41, 57, 66, 67, 
75-79, 84, 99, 116, 117, 121, 130] 
X  X X X X X    X X  X X X X X   X X 
Abbreviations: AVMD, Adult Vitelliform Macular Dystrophy; CSNB, Congenital Stationary Night Blindness; LCA, Leber Congenital Amaurosis; CRD, Cone-Rod 
Dystrophy; ABCA4, ATP Binding Cassette Subfamily A Member 4; BEST1, Bestrophin 1; C8orf37, Chromosome 8 Open Reading Frame 37; CERKL, Ceramide Kinase 
Like; CNGA3, Cyclic Nucleotide Gated Channel Subunit Alpha 3; CRB1, Crumbs Cell Polarity Complex Component 1; CRX, Cone-Rod Homeobox; IMPDH1, Inosine 
Monophosphate Dehydrogenase 1; LRAT, Lecithin Retinol Acyltransferase; PDE6, Phosphodiesterase 6; PROM1, Prominin 1; PRPH2, Peripherin 2; RHO, Rhodopsin; 
RDH12, Retinol Dehydrogenase 12; RP1, RP1 Axonemal Microtubule Associated; RPE65, Retinoid Isomerohydrolase RPE65; RPGR, Retinitis Pigmentosa GTPase 
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Table 6. Abbreviations used in the text 
Abbreviation Full description 
AVMD Adult onset Vitelliform Macular Dystrophy 
ABC ATP-Binding Cassette transporter protein 
adRP autosomal dominant RP 
adSTGD1 autosomal dominant STGD1-like 
arB autosomal recessive bestrophinopathy 
arRP autosomal recessive RP 
arSTGD1 autosomal recessive Stargardt Disease 
BBS Bardet-Biedl Syndrome 
BVMD Best Vitelliform Macular Dystrophy 
CTL C-Type Lectin 
CCO Carotenoid Cleavage Oxygenase 
CD Cone Dystrophy 
CRD Cone-Rod Dystrophy 
CSNB Congenital Stationary Night Blindness 
CC Connecting Cilium 
CRB1 CRumBs Homologue 1 
cGMP Cyclic Guanosine MonoPhosphate 
CME Cystoid Macular Edema 
DBD DNA-Binding Domain 
ERG ElectroRetinoGram 
ESC Enhanced S-Cone syndrome 
EGF Epidermal Growth Factor 
ffERG Full-Field ERG 
GPCR G Protein Coupled Receptors 
iPSCs Induced Pluripotent Stem Cells 
IRDs Inherited Retinal Diseases 
IS Inner Segment 
LCA Leber Congenital Amaurosis 
LBD Ligand-Binding Domain 
MD Macular Dystrophies 
mERG Multifocal ERG 
NRPE N-Retinylidene-PhosphatidylEthanolamine 
NGS Next-Generation Sequencing 
OCT Optical Coherence Tomography 
OSs Outer Segments 
PRPH2 Peripherin 2 
PE PhosphatidylEthanolamine 
PDE6 PhosphoDiEsterase 6 
PRPF31 PRe-mRNA Processing Factor 31 
PROM-1 PROMinin like-1 
RPE Retinal Pigment Epithelium 
RP Retinitis Pigmentosa 
RP1 Retinitis Pigmentosa 1 
RP2 Retinitis Pigmentosa 2  
RP4 Retinitis Pigmentosa 4 
RPGR Retinitis Pigmentosa GTPase Regulator 
RPGRIP1 Retinitis Pigmentosa GTPase Regulator Interacting Protein 1 
RHO RHodOpsin 
RCD Rod-Cone Dystrophy 
snRNP Small Nuclear RiboNucleoProtein 
TULP1 TUbby-Like Protein 1 
USH2 USHer Syndrome Type 2 
VMD Vitelliform Macular Dystrophy 
XLCD X-Linked Cone Dystrophy 
XLMD X-Linked Macular Dystrophy 
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CONCLUSIONS 
RP is a genetically complicated and heterogeneous 
disease. To date, approximately 80 genes have been 
implicated in non-syndromic RP and 30 genes in 
syndromic RP. The extreme heterogeneity that 
characterizes RP has led to many attempts to map and 
analyze the genes that contribute to the appearance and 
progression of several RP forms, a demanding task as 
these genes belong to several groups (i.e., genes that 
encode proteins of the visual cascade, genes encoding 
proteins of the visual cycle, mitochondrial genes, etc.). To 
date, approximately 27 adRP, 55 arRP, and 6 xlRP genes 
have been reported to be pathogenic according to the 
RetNet and Genecards databases, whereas several genes 
may be implicated in different patterns of RP inheritance. 
RHO is the gene most often associated with adRP, USH2A 
with arRP, and RPGR with xlRP. 
Specific genotyping microarrays, gene-by-gene 
analysis by Sanger sequencing, linkage mapping, NGS, 
and deletion detection are mainly used for the genetic 
diagnosis of IRDs, including RP. The main long-term 
objective of research on mutations associated with RP 
pathogenesis is the adoption of wide genetic testing. 
This may provide appropriate information for clinical 
care and counseling of patients with RP. The 
expectation is that the eventual verification of disease 
pathology will offer novel treatments and cure. The 
ultimate research target is to permit the 
interpretation of variants and reconciliation of the 
diagnosis with molecular findings. Such an eventuality 
will provide meaningful information to clinicians and 
provide useful counseling to patients. Thus, it is 
crucial for future studies to attempt an analysis and 
detailed mapping of the genes that contribute to the 
appearance and progression of each type of RP. 
In addition, a detailed map of RP pathogenic genes could 
provide vital information for future research on RP 
genetics and therapy methods, particularly gene therapy. 
By presenting the major genes involved in RP 
pathogenesis, future therapy methods may focus on exact 
mutations and variants that provide accurate treatment 
by targeting specific loci.  
 
ETHICS DECLARATIONS 
Ethical approval: This study was an observational 
bibliographic study and no ethical approval was required. 
Conflict of interest: The authors have no conflicts of 









1. Huang L, Zhang Q, Huang X, Qu C, Ma S, Mao Y, et al. Mutation 
screening in genes known to be responsible for Retinitis 
Pigmentosa in 98 Small Han Chinese Families. Sci Rep. 
2017;7(1):1948. doi: 10.1038/s41598-017-00963-6 pmid: 
28512305 
2. Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and 
mutations causing retinitis pigmentosa Arch Ophthalmol. 
2007;125(2):151-8. doi: 10.1001/archopht.125.2.151 pmid: 
17296890 
3. Perez-Carro R, Corton M, Sanchez-Navarro I, Zurita O, Sanchez-
Bolivar N, Sanchez-Alcudia R, et al. Panel-based NGS Reveals Novel 
Pathogenic Mutations in Autosomal Recessive Retinitis 
Pigmentosa. Sci Rep. 2016;6:19531. doi: 10.1038/srep19531 
pmid: 26806561 
4. Ezquerra-Inchausti M, Barandika O, Anasagasti A, Irigoyen C, 
Lopez de Munain A, Ruiz-Ederra J. High prevalence of mutations 
affecting the splicing process in a Spanish cohort with autosomal 
dominant retinitis pigmentosa. Sci Rep. 2017;7:39652. doi: 
10.1038/srep39652 pmid: 28045043 
5. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40. 
doi: 10.1186/1750-1172-1-40 pmid: 17032466 
6. Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing 
retinitis pigmentosa. Clin Genet. 2013;84(2):132-41. doi: 
10.1111/cge.12203 pmid: 23701314 
7. Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, 
Klaver CCW, et al. Non-syndromic retinitis pigmentosa. Prog Retin 
Eye Res. 2018;66:157-86. doi: 10.1016/j.preteyeres.2018.03.005 
pmid: 29597005 
8. Pagon RA. Retinitis pigmentosa. Surv Ophthalmol. 
1988;33(3):137-77. doi: 10.1016/0039-6257(88)90085-9 pmid: 
3068820 
9. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 
2006;368(9549):1795-809. doi: 10.1016/S0140-6736(06)69740-7 
pmid: 17113430 
10. Jiang J, Wu X, Shen D, Dong L, Jiao X, Hejtmancik JF, et al. Analysis 
of RP2 and RPGR Mutations in Five X-Linked Chinese Families with 
Retinitis Pigmentosa. Sci Rep. 2017;7:44465. doi: 
10.1038/srep44465 pmid: 28294154 
11. Wang J, Xu D, Zhu T, Zhou Y, Chen X, Wang F, et al. Identification 
of two novel RHO mutations in Chinese retinitis pigmentosa 
patients. Exp Eye Res. 2019;188:107726. doi: 
10.1016/j.exer.2019.107726 pmid: 31319082 
12. Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, 
Parmeggiani F. Retinitis pigmentosa: genes and disease 
mechanisms. Curr Genomics. 2011;12(4):238-49. doi: 
10.2174/138920211795860107 pmid: 22131869 
13. Akkaya S. Rate of Parental Consanguineous Marriage among 
Patients with Visual Impairments in Turkey. Med Hypothesis 
Discov Innov Ophthalmol. 2016;5(4):115-20. pmid: 28293658 
  
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
250 RECENT DEVELOPMENTS IN RETINITIS PIGMENTOSA GENETICS 
14. Ali MU, Rahman MSU, Cao J, Yuan PX. Genetic characterization 
and disease mechanism of retinitis pigmentosa; current scenario. 
3 Biotech. 2017;7(4):251. doi: 10.1007/s13205-017-0878-3 pmid: 
28721681 
15. Chen X, Sheng X, Liu Y, Li Z, Sun X, Jiang C, et al. Distinct mutations 
with different inheritance mode caused similar retinal dystrophies 
in one family: a demonstration of the importance of genetic 
annotations in complicated pedigrees. J Transl Med. 
2018;16(1):145. doi: 10.1186/s12967-018-1522-7 pmid: 
29843741 
16. Domanico D, Fragiotta S, Cutini A, Grenga PL, Vingolo EM. 
Psychosis, Mood and Behavioral Disorders in Usher Syndrome: 
Review of the Literature. Med Hypothesis Discov Innov 
Ophthalmol. 2015;4(2):50-5. pmid: 26060830 
17. Abdulridha-Aboud W, Kjellstrom U, Andreasson S, Ponjavic V. 
Characterization of macular structure and function in two Swedish 
families with genetically identified autosomal dominant retinitis 
pigmentosa. Mol Vis. 2016;22:362-73. pmid: 27212874 
18. Sun X, Park JH, Gumerson J, Wu Z, Swaroop A, Qian H, et al. Loss 
of RPGR glutamylation underlies the pathogenic mechanism of 
retinal dystrophy caused by TTLL5 mutations. Proc Natl Acad Sci U 
S A. 2016;113(21):E2925-34. doi: 10.1073/pnas.1523201113 
pmid: 27162334 
19. Phelan JK, Bok D. A brief review of retinitis pigmentosa and the 
identified retinitis pigmentosa genes. Mol Vis. 2000;6:116-24. 
pmid: 10889272 
20. Daiger SP, Bowne SJ, Sullivan LS. Genes and Mutations Causing 
Autosomal Dominant Retinitis Pigmentosa. Cold Spring Harb 
Perspect Med. 2014;5(10):a017129. doi: 
10.1101/cshperspect.a017129 pmid: 25304133 
21. Kabir F, Ullah I, Ali S, Gottsch AD, Naeem MA, Assir MZ, et al. Loss 
of function mutations in RP1 are responsible for retinitis 
pigmentosa in consanguineous familial cases. Mol Vis. 
2016;22:610-25. pmid: 27307693 
22. Uy HS, Chan PS, Cruz FM. Stem cell therapy: a novel approach for 
vision restoration in retinitis pigmentosa. Med Hypothesis Discov 
Innov Ophthalmol. 2013;2(2):52-5. pmid: 24600643 
23. Panfoli I. Beneficial effect of antioxidants in retinopathies: a new 
hypothesis. Med Hypothesis Discov Innov Ophthalmol. 
2012;1(4):76-9. pmid: 24600629 
24. Van Cauwenbergh C, Coppieters F, Roels D, De Jaegere S, Flipts H, 
De Zaeytijd J, et al. Mutations in Splicing Factor Genes Are a Major 
Cause of Autosomal Dominant Retinitis Pigmentosa in Belgian 
Families. PLoS One. 2017;12(1):e0170038. doi: 
10.1371/journal.pone.0170038 pmid: 28076437 
25. Yu X, Shi W, Cheng L, Wang Y, Chen D, Hu X, et al. Identification of 
a rhodopsin gene mutation in a large family with autosomal 
dominant retinitis pigmentosa. Sci Rep. 2016;6:19759. doi: 
10.1038/srep19759 pmid: 26794436 
26. Beryozkin A, Levy G, Blumenfeld A, Meyer S, Namburi P, Morad Y, 
et al. Genetic Analysis of the Rhodopsin Gene Identifies a Mosaic 
Dominant Retinitis Pigmentosa Mutation in a Healthy Individual. 
Invest Ophthalmol Vis Sci. 2016;57(3):940-7. doi: 10.1167/iovs.15-
18702 pmid: 26962691 
27. Martin-Merida I, Aguilera-Garcia D, Fernandez-San Jose P, Blanco-
Kelly F, Zurita O, Almoguera B, et al. Toward the Mutational 
Landscape of Autosomal Dominant Retinitis Pigmentosa: A 
Comprehensive Analysis of 258 Spanish Families. Invest 
Ophthalmol Vis Sci. 2018;59(6):2345-54. doi: 10.1167/iovs.18-
23854 pmid: 29847639 
28. Roshandel D, Rafati M, Khorami S, Novin Baheran N, Jalali S, 
Tabatabaie R, et al. Rhodopsin gene mutation analysis in Iranian 
patients with autosomal dominant retinitis pigmentosa. Int 
Ophthalmol. 2019;39(11):2523-31. doi: 10.1007/s10792-019-
01099-4 pmid: 30972525 
29. Koyanagi Y, Akiyama M, Nishiguchi KM, Momozawa Y, Kamatani 
Y, Takata S, et al. Genetic characteristics of retinitis pigmentosa in 
1204 Japanese patients. J Med Genet. 2019;56(10):662-70. doi: 
10.1136/jmedgenet-2018-105691 pmid: 31213501 
30. Kim MS, Joo K, Seong MW, Kim MJ, Park KH, Park SS, et al. Genetic 
Mutation Profiles in Korean Patients with Inherited Retinal 
Diseases. J Korean Med Sci. 2019;34(21):e161. doi: 
10.3346/jkms.2019.34.e161 pmid: 31144483 
31. Conley SM, Stuck MW, Watson JN, Naash MI. Rom1 converts 
Y141C-Prph2-associated pattern dystrophy to retinitis 
pigmentosa. Hum Mol Genet. 2017;26(3):509-18. doi: 
10.1093/hmg/ddw408 pmid: 28053051 
32. Tsokolas G, Almuhtaseb H, Griffiths H, Shawkat F, Pengelly RJ, 
Sarah E, et al. Long term follow-up of a family with GUCY2D 
dominant cone dystrophy. Int J Ophthalmol. 2018;11(12):1945-50. 
doi: 10.18240/ijo.2018.12.12 pmid: 30588428 
33. Birtel J, Eisenberger T, Gliem M, Muller PL, Herrmann P, Betz C, et 
al. Clinical and genetic characteristics of 251 consecutive patients 
with macular and cone/cone-rod dystrophy. Sci Rep. 
2018;8(1):4824. doi: 10.1038/s41598-018-22096-0 pmid: 
29555955 
34. Birtel J, Gliem M, Mangold E, Muller PL, Holz FG, Neuhaus C, et al. 
Next-generation sequencing identifies unexpected genotype-
phenotype correlations in patients with retinitis pigmentosa. PLoS 
One. 2018;13(12):e0207958. doi: 10.1371/journal.pone.0207958 
pmid: 30543658 
35. Huang H, Wang Y, Chen H, Chen Y, Wu J, Chiang PW, et al. Targeted 
next generation sequencing identified novel mutations in RPGRIP1 
associated with both retinitis pigmentosa and Leber's congenital 
amaurosis in unrelated Chinese patients. Oncotarget. 
2017;8(21):35176-83. doi: 10.18632/oncotarget.17052 pmid: 
28456785 
36. Xiang Q, Cao Y, Xu H, Guo Y, Yang Z, Xu L, et al. Identification of 
novel pathogenic ABCA4 variants in a Han Chinese family with 
STGD. Biosci Rep. 2019;39(1). doi: 10.1042/BSR20180872 pmid: 
30563929 
37. Brandl C, Schulz HL, Charbel Issa P, Birtel J, Bergholz R, Lange C, et 
al. Mutations in the Genes for Interphotoreceptor Matrix 
Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform 
Macular Lesions. Genes (Basel). 2017;8(7). doi: 
10.3390/genes8070170 pmid: 28644393 
38. Grunin M, Tiosano L, Jaouni T, Averbukh E, Sharon D, Chowers I. 
Evaluation of the association of single nucleotide polymorphisms 
in the PRPH2 gene with adult-onset foveomacular vitelliform 
dystrophy. Ophthalmic Genet. 2016;37(3):285-9. doi: 
10.3109/13816810.2015.1059456 pmid: 26849151 
39. Liu S, Xie L, Yue J, Ma T, Peng C, Qiu B, et al. Whole-exome 
sequencing identifies a novel homozygous frameshift mutation in 
the PROM1 gene as a causative mutation in two patients with 
sporadic retinitis pigmentosa. Int J Mol Med. 2016;37(6):1528-34. 
doi: 10.3892/ijmm.2016.2551 pmid: 27082927 
40. Lu L, Wang X, Lo D, Weng J, Liu X, Yang J, et al. Novel mutations in 
CRB1 gene identified in a chinese pedigree with retinitis 
pigmentosa by targeted capture and next generation sequencing. 
Oncotarget. 2016;7(48):79797-804. doi: 
10.18632/oncotarget.12971 pmid: 27806333 
  
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
251 RECENT DEVELOPMENTS IN RETINITIS PIGMENTOSA GENETICS 
41. Ravesh Z, El Asrag ME, Weisschuh N, McKibbin M, Reuter P, 
Watson CM, et al. Novel C8orf37 mutations cause retinitis 
pigmentosa in consanguineous families of Pakistani origin. Mol 
Vis. 2015;21:236-43. pmid: 25802487 
42. Parmeggiani F, Barbaro V, Migliorati A, Raffa P, Nespeca P, De 
Nadai K, et al. Novel variants of RPGR in X-linked retinitis 
pigmentosa families and genotype-phenotype correlation. Eur J 
Ophthalmol. 2017;27(2):240-8. doi: 10.5301/ejo.5000879 pmid: 
27768226 
43. Manes G, Guillaumie T, Vos WL, Devos A, Audo I, Zeitz C, et al. High 
prevalence of PRPH2 in autosomal dominant retinitis pigmentosa 
in france and characterization of biochemical and clinical features. 
Am J Ophthalmol. 2015;159(2):302-14. doi: 
10.1016/j.ajo.2014.10.033 pmid: 25447119 
44. Zhong Z, Yan M, Sun W, Wu Z, Han L, Zhou Z, et al. Two novel 
mutations in PRPF3 causing autosomal dominant retinitis 
pigmentosa. Sci Rep. 2016;6:37840. doi: 10.1038/srep37840 
pmid: 27886254 
45. Xiao J, Guo X, Wang Y, Shao M, Wei X, Du L, et al. Identification of 
a Disease-Causing Mutation in a Chinese Patient with Retinitis 
Pigmentosa by Targeted Next-Generation Sequencing. Eur J 
Ophthalmol. 2017;27(6):791-6. doi: 10.5301/ejo.5000971 pmid: 
28430325 
46. Wu Z, Zhong M, Li M, Huang H, Liao J, Lu A, et al. Mutation Analysis 
of Pre-mRNA Splicing Genes PRPF31, PRPF8, and SNRNP200 in 
Chinese Families with Autosomal Dominant Retinitis Pigmentosa. 
Curr Mol Med. 2018;18(5):287-94. doi: 
10.2174/1566524018666181024160452 pmid: 30360737 
47. Chen X, Liu Y, Sheng X, Tam PO, Zhao K, Chen X, et al. PRPF4 
mutations cause autosomal dominant retinitis pigmentosa. Hum 
Mol Genet. 2014;23(11):2926-39. doi: 10.1093/hmg/ddu005 
pmid: 24419317 
48. Yang Y, Tian D, Lee J, Zeng J, Zhang H, Chen S, et al. Clinical and 
genetic identification of a large chinese family with autosomal 
dominant retinitis pigmentosa. Ophthalmic Genet. 2015;36(1):64-
9. doi: 10.3109/13816810.2013.809458 pmid: 23834559 
49. Rose AM, Luo R, Radia UK, Bhattacharya SS. Gene of the month: 
PRPF31. J Clin Pathol. 2017;70(9):729-32. doi: 10.1136/jclinpath-
2016-203971 pmid: 28663330 
50. Xiao X, Cao Y, Zhang Z, Xu Y, Zheng Y, Chen LJ, et al. Novel 
Mutations in PRPF31 Causing Retinitis Pigmentosa Identified Using 
Whole-Exome Sequencing. Invest Ophthalmol Vis Sci. 
2017;58(14):6342-50. doi: 10.1167/iovs.17-22952 pmid: 
29260190 
51. Rose AM, Shah AZ, Venturini G, Krishna A, Chakravarti A, Rivolta C, 
et al. Transcriptional regulation of PRPF31 gene expression by 
MSR1 repeat elements causes incomplete penetrance in retinitis 
pigmentosa. Sci Rep. 2016;6:19450. doi: 10.1038/srep19450 
pmid: 26781568 
52. Xie D, Peng K, Yi Q, Liu W, Yang Y, Sun K, et al. Targeted Next 
Generation Sequencing Revealed Novel PRPF31 Mutations in 
Autosomal Dominant Retinitis Pigmentosa. Genet Test Mol 
Biomarkers. 2018;22(7):425-32. doi: 10.1089/gtmb.2018.0036 
pmid: 29957067 
53. Martin-Merida I, Sanchez-Alcudia R, Fernandez-San Jose P, 
Blanco-Kelly F, Perez-Carro R, Rodriguez-Jacy da Silva L, et al. 
Analysis of the PRPF31 Gene in Spanish Autosomal Dominant 
Retinitis Pigmentosa Patients: A Novel Genomic Rearrangement. 
Invest Ophthalmol Vis Sci. 2017;58(2):1045-53. doi: 
10.1167/iovs.16-20515 pmid: 28192796 
54. Zahid S, Branham K, Schlegel D, Pennesi ME, Michaelides M, 
Heckenlively J, et al. Retinal dystrophy gene atlas. Berlin: Springer; 
2018. 
55. Riera M, Abad-Morales V, Navarro R, Ruiz-Nogales S, Mendez-
Vendrell P, Corcostegui B, et al. Expanding the retinal phenotype 
of RP1: from retinitis pigmentosa to a novel and singular macular 
dystrophy. Br J Ophthalmol. 2020;104(2):173-81. doi: 
10.1136/bjophthalmol-2018-313672 pmid: 31079053 
56. Kurata K, Hosono K, Hotta Y. Clinical and genetic findings of a 
Japanese patient with RP1-related autosomal recessive retinitis 
pigmentosa. Doc Ophthalmol. 2018;137(1):47-56. doi: 
10.1007/s10633-018-9649-7 pmid: 30027431 
57. Verbakel SK, van Huet RAC, den Hollander AI, Geerlings MJ, 
Kersten E, Klevering BJ, et al. Macular Dystrophy and Cone-Rod 
Dystrophy Caused by Mutations in the RP1 Gene: Extending the 
RP1 Disease Spectrum. Invest Ophthalmol Vis Sci. 
2019;60(4):1192-203. doi: 10.1167/iovs.18-26084 pmid: 
30913292 
58. Wang L, Qi A, Pan H, Liu B, Feng J, Chen W, et al. A novel CRX 
frameshift mutation causing cone-rod dystrophy in a Chinese 
family: A case report. Medicine (Baltimore). 2018;97(32):e11499. 
doi: 10.1097/MD.0000000000011499 pmid: 30095615 
59. Zhu Y, Tan H, Zeng J, Tao D, Ma Y, Liu Y. A novel CRX variant 
(p.R98X) is identified in a Chinese family of Retinitis pigmentosa 
with atypical and mild manifestations. Genes Genomics. 
2019;41(3):359-66. doi: 10.1007/s13258-018-0763-4 pmid: 
30460480 
60. Chapi M, Sabbaghi H, Suri F, Alehabib E, Rahimi-Aliabadi S, Jamali 
F, et al. Incomplete penetrance of CRX gene for autosomal 
dominant form of cone-rod dystrophy. Ophthalmic Genet. 
2019;40(3):259-66. doi: 10.1080/13816810.2019.1622023 pmid: 
31215831 
61. Walia S, Fishman GA, Jacobson SG, Aleman TS, Koenekoop RK, 
Traboulsi EI, et al. Visual acuity in patients with Leber's congenital 
amaurosis and early childhood-onset retinitis pigmentosa. 
Ophthalmology. 2010;117(6):1190-8. doi: 
10.1016/j.ophtha.2009.09.056 pmid: 20079931 
62. Jauregui R, Park KS, Tsang SH. Two-year progression analysis of 
RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic 
Genet. 2018;39(4):544-9. doi: 10.1080/13816810.2018.1484929 
pmid: 29947567 
63. Choi E, Suh S, Sander C, Hernandez C, Bulman E, Khadka N. Insights 
into the pathogenesis of dominant retinitis pigmentosa associated 
with a D477G mutation in RPE65. Hum Mol Genet. 
2018;27(13):2225-43. doi: 10.1093/hmg/ddy128  
64. Hull S, Mukherjee R, Holder GE, Moore AT, Webster AR. The 
clinical features of retinal disease due to a dominant mutation in 
RPE65. Mol Vis. 2016;22:626-35. pmid: 27307694 
65. Glen WB, Jr., Peterseim MMW, Badilla R, Znoyko I, Bourg A, Wilson 
R, et al. A high prevalence of biallelic RPE65 mutations in Costa 
Rican children with Leber congenital amaurosis and early-onset 
retinal dystrophy. Ophthalmic Genet. 2019;40(2):110-7. doi: 
10.1080/13816810.2019.1582069 pmid: 30870047 
66. Hohman TC. Hereditary Retinal Dystrophy. Handb Exp Pharmacol. 
2017;242:337-67. doi: 10.1007/164_2016_91 pmid: 28035529 
67. Li S, Xiao X, Yi Z, Sun W, Wang P, Zhang Q. RPE65 mutation 
frequency and phenotypic variation according to exome 
sequencing in a tertiary centre for genetic eye diseases in China. 




Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
252 RECENT DEVELOPMENTS IN RETINITIS PIGMENTOSA GENETICS 
68. Chebil A, Falfoul Y, Habibi I, Munier F, Schorderet D, El Matri L. 
[Genotype-phenotype correlation in ten Tunisian families with 
non-syndromic retinitis pigmentosa]. J Fr Ophtalmol. 
2016;39(3):277-86. doi: 10.1016/j.jfo.2015.08.013 pmid: 
26868535 
69. Jakobsson C, Othman IS, Munier FL, Schorderet DF, Abouzeid H. 
Cone-rod dystrophy caused by a novel homozygous RPE65 
mutation in Leber congenital amaurosis. Klin Monbl Augenheilkd. 
2014;231(4):405-10. doi: 10.1055/s-0034-1368221 pmid: 
24771178 
70. Astuti GD, Bertelsen M, Preising MN, Ajmal M, Lorenz B, Faradz 
SM, et al. Comprehensive genotyping reveals RPE65 as the most 
frequently mutated gene in Leber congenital amaurosis in 
Denmark. Eur J Hum Genet. 2016;24(7):1071-9. doi: 
10.1038/ejhg.2015.241 pmid: 26626312 
71. Liu J, Bu J. A Gene Scan Study of RPE65 in Chinese Patients with 
Leber Congenital Amaurosis. Chin Med J (Engl). 
2017;130(22):2709-12. doi: 10.4103/0366-6999.218007 pmid: 
29133760 
72. Smaragda K, Vassiliki K, George K, Polixeni S, Christoforos G, 
Anastasios A, et al. Mutation Spectrum of the ABCA4 Gene in a 
Greek Cohort with Stargardt Disease: Identification of Novel 
Mutations and Evidence of Three Prevalent Mutated Alleles. J 
Ophthalmol. 2018;2018:5706142. doi: 10.1155/2018/5706142 
pmid: 29854428 
73. Huang L, Zhang Q, Li S, Guan L, Xiao X, Zhang J, et al. Exome 
sequencing of 47 chinese families with cone-rod dystrophy: 
mutations in 25 known causative genes. PLoS One. 
2013;8(6):e65546. doi: 10.1371/journal.pone.0065546 pmid: 
23776498 
74. Makelainen S, Godia M, Hellsand M, Viluma A, Hahn D, Makdoumi 
K, et al. An ABCA4 loss-of-function mutation causes a canine form 
of Stargardt disease. PLoS Genet. 2019;15(3):e1007873. doi: 
10.1371/journal.pgen.1007873 pmid: 30889179 
75. Huang X, Yuan L, Xu H, Zheng W, Cao Y, Yi J, et al. Identification of 
a Novel Mutation in the ABCA4 Gene in a Chinese Family with 
Retinitis Pigmentosa Using Exome Sequencing. Biosci Rep. 
2018;38(2). doi: 10.1042/BSR20171300 pmid: 29437900 
76. Sheremet NL, Grushke IG, Zhorzholadze NV, Ronzina IA, Mikaelyan 
AA, Tanas AS, et al. [Clinical polymorphism of splice site mutations 
in the ABCA4 gene]. Vestn Oftalmol. 2018;134(6):83-93. doi: 
10.17116/oftalma201813406183 pmid: 30721205 
77. Jiang F, Pan Z, Xu K, Tian L, Xie Y, Zhang X, et al. Screening of ABCA4 
Gene in a Chinese Cohort With Stargardt Disease or Cone-Rod 
Dystrophy With a Report on 85 Novel Mutations. Invest 
Ophthalmol Vis Sci. 2016;57(1):145-52. doi: 10.1167/iovs.15-
18190 pmid: 26780318 
78. Sheremet NL, Grushke IG, Zhorzholadze NV, Tanas AS, Strelnikov 
VV. [Inherited retinal diseases in patients with ABCA4 gene 
mutations]. Vestn Oftalmol. 2018;134(4):68-73. doi: 
10.17116/oftalma201813404168 pmid: 30166513 
79. Biswas P, Duncan JL, Maranhao B, Kozak I, Branham K, Gabriel L, 
et al. Genetic analysis of 10 pedigrees with inherited retinal 
degeneration by exome sequencing and phenotype-genotype 
association. Physiol Genomics. 2017;49(4):216-29. doi: 
10.1152/physiolgenomics.00096.2016 pmid: 28130426 
80. Mayer AK, Rohrschneider K, Strom TM, Glockle N, Kohl S, 
Wissinger B, et al. Homozygosity mapping and whole-genome 
sequencing reveals a deep intronic PROM1 mutation causing 
cone-rod dystrophy by pseudoexon activation. Eur J Hum Genet. 
2016;24(3):459-62. doi: 10.1038/ejhg.2015.144 pmid: 26153215 
81. Sharon D, Ben-Yosef T, Pras E, Goldenberg-Cohen N, Gradstein L, 
Shomron N, et al. [the Israeli Inherited Retinal Diseases 
Consortium (Iirdc)- Clinical-Genetic Mapping and Future 
Perspectives]. Harefuah. 2019;158(2):91-5. pmid: 30779484 
82. Quinn PM, Mulder AA, Henrique Alves C, Desrosiers M, de Vries SI, 
Klooster J, et al. Loss of CRB2 in Muller glial cells modifies a CRB1-
associated retinitis pigmentosa phenotype into a Leber congenital 
amaurosis phenotype. Hum Mol Genet. 2019;28(1):105-23. doi: 
10.1093/hmg/ddy337 pmid: 30239717 
83. Wawrocka A, Skorczyk-Werner A, Wicher K, Niedziela Z, Ploski R, 
Rydzanicz M, et al. Novel variants identified with next-generation 
sequencing in Polish patients with cone-rod dystrophy. Mol Vis. 
2018;24:326-39. pmid: 29769798 
84. Liang J, She X, Chen J, Zhai Y, Liu Y, Zheng K, et al. Identification of 
novel PROM1 mutations responsible for autosomal recessive 
maculopathy with rod-cone dystrophy. Graefes Arch Clin Exp 
Ophthalmol. 2019;257(3):619-28. doi: 10.1007/s00417-018-
04206-w pmid: 30588538 
85. Schroeder M, Kjellstrom U. Full-field ERG as a predictor of the 
natural course of ABCA4-associated retinal degenerations. Mol 
Vis. 2018;24:1-16. pmid: 29386879 
86. Motta FL, Salles MV, Costa KA, Filippelli-Silva R, Martin RP, Sallum 
JMF. The correlation between CRB1 variants and the clinical 
severity of Brazilian patients with different inherited retinal 
dystrophy phenotypes. Sci Rep. 2017;7(1):8654. doi: 
10.1038/s41598-017-09035-1 pmid: 28819299 
87. Khan KN, Robson A, Mahroo OAR, Arno G, Inglehearn CF, 
Armengol M, et al. A clinical and molecular characterisation of 
CRB1-associated maculopathy. Eur J Hum Genet. 2018;26(5):687-
94. doi: 10.1038/s41431-017-0082-2 pmid: 29391521 
88. Yang Y, Yang Y, Huang L, Zhai Y, Li J, Jiang Z, et al. Whole exome 
sequencing identified novel CRB1 mutations in Chinese and Indian 
populations with autosomal recessive retinitis pigmentosa. Sci 
Rep. 2016;6:33681. doi: 10.1038/srep33681 pmid: 27670293 
89. Shen T, Guan L, Li S, Zhang J, Xiao X, Jiang H, et al. Mutation 
analysis of Leber congenital amaurosisassociated genes in patients 
with retinitis pigmentosa. Mol Med Rep. 2015;11(3):1827-32. doi: 
10.3892/mmr.2014.2894 pmid: 25377065 
90. Srilekha S, Arokiasamy T, Srikrupa NN, Umashankar V, Meenakshi 
S, Sen P, et al. Homozygosity Mapping in Leber Congenital 
Amaurosis and Autosomal Recessive Retinitis Pigmentosa in South 
Indian Families. PLoS One. 2015;10(7):e0131679. doi: 
10.1371/journal.pone.0131679 pmid: 26147992 
91. Talib M, van Schooneveld MJ, van Genderen MM, Wijnholds J, 
Florijn RJ, Ten Brink JB, et al. Genotypic and Phenotypic 
Characteristics of CRB1-Associated Retinal Dystrophies: A Long-
Term Follow-up Study. Ophthalmology. 2017;124(6):884-95. doi: 
10.1016/j.ophtha.2017.01.047 pmid: 28341475 
92. Guo X, Li J, Wang Q, Shu Y, Wang J, Chen L, et al. Identification of 
CRB1 mutations in two Chinese consanguineous families 
exhibiting autosomal recessive retinitis pigmentosa. Mol Med 
Rep. 2019;20(3):2922-8. doi: 10.3892/mmr.2019.10495 pmid: 
31322236 
93. Saberi M, Golchehre Z, Karamzade A, Entezam M, Eshaghkhani Y, 
Alavinejad E, et al. CRB1-Related Leber Congenital Amaurosis: 
Reporting Novel Pathogenic Variants and a Brief Review on 
Mutations Spectrum. Iran Biomed J. 2019;23(5):362-8. pmid: 
31103025 
94. Khan AO, Aldahmesh MA, Abu-Safieh L, Alkuraya FS. Childhood 
cone-rod dystrophy with macular cystic degeneration from 
  
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
253 RECENT DEVELOPMENTS IN RETINITIS PIGMENTOSA GENETICS 
recessive CRB1 mutation. Ophthalmic Genet. 2014;35(3):130-7. 
doi: 10.3109/13816810.2013.804097 pmid: 23767994 
95. Mathijssen IB, Florijn RJ, van den Born LI, Zekveld-Vroon RC, Ten 
Brink JB, Plomp AS, et al. Long-term follow-up of patients with 
retinitis pigmentosa type 12 caused by CRB1 mutations: a severe 
phenotype with considerable interindividual variability. Retina. 
2017;37(1):161-72. doi: 10.1097/IAE.0000000000001127 pmid: 
27380427 
96. Jinda W, Taylor TD, Suzuki Y, Thongnoppakhun W, Limwongse C, 
Lertrit P, et al. Whole exome sequencing in Thai patients with 
retinitis pigmentosa reveals novel mutations in six genes. Invest 
Ophthalmol Vis Sci. 2014;55(4):2259-68. doi: 10.1167/iovs.13-
13567 pmid: 24618324 
97. Weisschuh N, Feldhaus B, Khan MI, Cremers FPM, Kohl S, 
Wissinger B, et al. Molecular and clinical analysis of 27 German 
patients with Leber congenital amaurosis. PLoS One. 
2018;13(12):e0205380. doi: 10.1371/journal.pone.0205380 pmid: 
30576320 
98. Del Pozo-Valero M, Martin-Merida I, Jimenez-Rolando B, Arteche 
A, Avila-Fernandez A, Blanco-Kelly F, et al. Expanded Phenotypic 
Spectrum of Retinopathies Associated with Autosomal Recessive 
and Dominant Mutations in PROM1. Am J Ophthalmol. 
2019;207:204-14. doi: 10.1016/j.ajo.2019.05.014 pmid: 31129250 
99. Arrigoni FI, Matarin M, Thompson PJ, Michaelides M, McClements 
ME, Redmond E, et al. Extended extraocular phenotype of PROM1 
mutation in kindreds with known autosomal dominant macular 
dystrophy. Eur J Hum Genet. 2011;19(2):131-7. doi: 
10.1038/ejhg.2010.147 pmid: 20859302 
100. Permanyer J, Navarro R, Friedman J, Pomares E, Castro-
Navarro J, Marfany G, et al. Autosomal recessive retinitis 
pigmentosa with early macular affectation caused by premature 
truncation in PROM1. Invest Ophthalmol Vis Sci. 2010;51(5):2656-
63. doi: 10.1167/iovs.09-4857 pmid: 20042663 
101. Sheremet NL, Zhorzholadze NV, Ronzina IA, Grushke IG, 
Kurbatov SA, Chukhrova AL, et al. [Molecular genetic diagnosis of 
STGD]. Vestn Oftalmol. 2017;133(4):4-11. doi: 
10.17116/oftalma201713344-11 pmid: 28980559 
102. Cehajic-Kapetanovic J, Birtel J, McClements ME, Shanks ME, 
Clouston P, Downes SM, et al. Clinical and Molecular 
Characterization of PROM1-Related Retinal Degeneration. JAMA 
Netw Open. 2019;2(6):e195752. doi: 
10.1001/jamanetworkopen.2019.5752 pmid: 31199449 
103. Palmowski-Wolfe A, Stingl K, Habibi I, Schorderet D, Tran 
HV. Novel PDE6B Mutation Presenting with Retinitis Pigmentosa - 
A Case Series of Three Patients. Klin Monbl Augenheilkd. 
2019;236(4):562-7. doi: 10.1055/a-0811-5480 pmid: 30646425 
104. Tsang SH, Sharma T. Retinitis Pigmentosa (Non-syndromic). 
Adv Exp Med Biol. 2018;1085:125-30. doi: 10.1007/978-3-319-
95046-4_25 pmid: 30578498 
105. Tatour Y, Tamaiev J, Shamaly S, Colombo R, Bril E, 
Rabinowitz T, et al. A novel intronic mutation of PDE6B is a major 
cause of autosomal recessive retinitis pigmentosa among 
Caucasus Jews. Mol Vis. 2019;25:155-64. pmid: 30820151 
106. Souzeau E, Thompson JA, McLaren TL, De Roach JN, Barnett 
CP, Lamey TM, et al. Maternal uniparental isodisomy of 
chromosome 6 unmasks a novel variant in TULP1 in a patient with 
early-onset retinal dystrophy. Mol Vis. 2018;24:478-84. pmid: 
30090012 
107. Ajmal M, Khan MI, Micheal S, Ahmed W, Shah A, Venselaar 
H, et al. Identification of recurrent and novel mutations in TULP1 
in Pakistani families with early-onset retinitis pigmentosa. Mol Vis. 
2012;18:1226-37. pmid: 22665969 
108. Ullah I, Kabir F, Iqbal M, Gottsch CB, Naeem MA, Assir MZ, 
et al. Pathogenic mutations in TULP1 responsible for retinitis 
pigmentosa identified in consanguineous familial cases. Mol Vis. 
2016;22:797-815. pmid: 27440997 
109. Kannabiran C, Singh H, Sahini N, Jalali S, Mohan G. 
Mutations in TULP1, NR2E3, and MFRP genes in Indian families 
with autosomal recessive retinitis pigmentosa. Mol Vis. 
2012;18:1165-74. pmid: 22605927 
110. Heon E, Kim G, Qin S, Garrison JE, Tavares E, Vincent A, et 
al. Mutations in C8ORF37 cause Bardet Biedl syndrome (BBS21). 
Hum Mol Genet. 2016;25(11):2283-94. doi: 
10.1093/hmg/ddw096 pmid: 27008867 
111. Khan AO, Decker E, Bachmann N, Bolz HJ, Bergmann C. 
C8orf37 is mutated in Bardet-Biedl syndrome and constitutes a 
locus allelic to non-syndromic retinal dystrophies. Ophthalmic 
Genet. 2016;37(3):290-3. doi: 10.3109/13816810.2015.1066830 
pmid: 26854863 
112. Wang J, Zhou C, Xiao Y, Liu H. Novel splice receptor-site 
mutation of RPGR in a Chinese family with X-linked retinitis 
pigmentosa. Medicine (Baltimore). 2018;97(41):e12779. doi: 
10.1097/MD.0000000000012779 pmid: 30313097 
113. Haddad MF, Khabour OF, Abuzaideh KA, Shihadeh W. 
Screening for mutations in RPGR and RP2 genes in Jordanian 
families with X-linked retinitis pigmentosa. Genet Mol Res. 
2016;15(2). doi: 10.4238/gmr.15027842 pmid: 27323122 
114. Beltran WA, Cideciyan AV, Lewin AS, Hauswirth WW, 
Jacobson SG, Aguirre GD. Gene augmentation for X-linked retinitis 
pigmentosa caused by mutations in RPGR. Cold Spring Harb 
Perspect Med. 2014;5(2):a017392. doi: 
10.1101/cshperspect.a017392 pmid: 25301933 
115. Sengillo JD, Fridman G, Cho GY, Buchovecky C, Tsang SH. 
Novel Mutation in Retinitis Pigmentosa GTPase Regulator Gene 
Causes Primary Ciliary Dyskinesia and Retinitis Pigmentosa. 
Ophthalmic Surg Lasers Imaging Retina. 2018;49(7):548-52. doi: 
10.3928/23258160-20180628-14 pmid: 30021045 
116. Talib M, van Schooneveld MJ, Thiadens AA, Fiocco M, 
Wijnholds J, Florijn RJ, et al. Clinical and genetic characteristics of 
male patients with RPGR-associated retinal dystrophies: A Long-
Term Follow-up Study. Retina. 2019;39(6):1186-99. doi: 
10.1097/IAE.0000000000002125 pmid: 29528978 
117. Huang L, Mao Y, Yang J, Li Y, Li Y, Yang Z. Mutation screening 
of the USH2A gene in retinitis pigmentosa and USHER patients in 
a Han Chinese population. Eye (Lond). 2018;32(10):1608-14. doi: 
10.1038/s41433-018-0130-3 pmid: 29899460 
118. Zhao Y, Hosono K, Suto K, Ishigami C, Arai Y, Hikoya A, et al. 
The first USH2A mutation analysis of Japanese autosomal 
recessive retinitis pigmentosa patients: a totally different 
mutation profile with the lack of frequent mutations found in 
Caucasian patients. J Hum Genet. 2014;59(9):521-8. doi: 
10.1038/jhg.2014.65 pmid: 25078356 
119. Nagase Y, Kurata K, Hosono K, Suto K, Hikoya A, Nakanishi 
H, et al. Visual Outcomes in Japanese Patients with Retinitis 
Pigmentosa and Usher Syndrome Caused by USH2A Mutations. 
Semin Ophthalmol. 2018;33(4):560-5. doi: 
10.1080/08820538.2017.1340487 pmid: 28678594 
120. Fu YC, Chen N, Qiu ZL, Liu L, Shen J. Compound pathogenic 
mutation in the USH2A gene in Chinese RP families detected by 
wholeexome sequencing. Mol Med Rep. 2018;18(6):5016-22. doi: 
10.3892/mmr.2018.9530 pmid: 30280194 
  
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
254 RECENT DEVELOPMENTS IN RETINITIS PIGMENTOSA GENETICS 
121. Aleman TS, Uyhazi KE, Serrano LW, Vasireddy V, Bowman 
SJ, Ammar MJ, et al. RDH12 Mutations Cause a Severe Retinal 
Degeneration With Relatively Spared Rod Function. Invest 
Ophthalmol Vis Sci. 2018;59(12):5225-36. doi: 10.1167/iovs.18-
24708 pmid: 30372751 
122. Gao T, Tian C, Hu Q, Liu Z, Zou J, Huang L, et al. Clinical and 
Mutation Analysis of Patients with Best Vitelliform Macular 
Dystrophy or Autosomal Recessive Bestrophinopathy in Chinese 
Population. Biomed Res Int. 2018;2018:4582816. doi: 
10.1155/2018/4582816 pmid: 30498755 
123. Guo J, Gao F, Tang W, Qi Y, Xuan Y, Liu W, et al. Novel Best1 
Mutations Detected by Next-Generation Sequencing in a Chinese 
Population with Vitelliform Macular Dystrophy. Retina. 
2019;39(8):1613-22. doi: 10.1097/IAE.0000000000002183 pmid: 
29781975 
124. Dalvin LA, Abou Chehade JE, Chiang J, Fuchs J, Iezzi R, 
Marmorstein AD. Retinitis pigmentosa associated with a mutation 
in BEST1. Am J Ophthalmol Case Rep. 2016;2:11-7. doi: 
10.1016/j.ajoc.2016.03.005 pmid: 29503890 
125. Eblimit A, Nguyen TM, Chen Y, Esteve-Rudd J, Zhong H, 
Letteboer S, et al. Spata7 is a retinal ciliopathy gene critical for 
correct RPGRIP1 localization and protein trafficking in the retina. 
Hum Mol Genet. 2015;24(6):1584-601. doi: 10.1093/hmg/ddu573 
pmid: 25398945 
126. Mahajan D, Votruba M. A novel NR2E3 gene mutation in 
autosomal recessive retinitis pigmentosa with cystic maculopathy. 
Acta Ophthalmol. 2018;96(4):e535-e6. doi: 10.1111/aos.13629 
pmid: 29193891 
127. Sato S, Morimoto T, Hotta K, Fujikado T, Nishida K. A novel 
compound heterozygous mutation in TTC8 identified in a 
Japanese patient. Hum Genome Var. 2019;6:14. doi: 
10.1038/s41439-019-0045-y pmid: 30886724 
128. Fingert JH, Oh K, Chung M, Scheetz TE, Andorf JL, Johnson 
RM, et al. Association of a novel mutation in the retinol 
dehydrogenase 12 (RDH12) gene with autosomal dominant 
retinitis pigmentosa. Arch Ophthalmol. 2008;126(9):1301-7. doi: 
10.1001/archopht.126.9.1301 pmid: 18779497 
129. Kohl S, Coppieters F, Meire F, Schaich S, Roosing S, 
Brennenstuhl C, et al. A nonsense mutation in PDE6H causes 
autosomal-recessive incomplete achromatopsia. Am J Hum 
Genet. 2012;91(3):527-32. doi: 10.1016/j.ajhg.2012.07.006 pmid: 
22901948 
130. Arshad MW, Lee Y, Malik MA, Khan J, Khan A, Kareem A, et 
al. Identification of Novel Mutation in CNGA3 gene by Whole-
Exome Sequencing and In-Silico Analyses for Genotype-Phenotype 
Assessment with Autosomal Recessive Achromatopsia in Pakistani 
families. J Pak Med Assoc. 2019;69(2):183-9. pmid: 30804581 
131. Sun W, Zhang Q. Diseases associated with mutations in 
CNGA3: Genotype-phenotype correlation and diagnostic 
guideline. Prog Mol Biol Transl Sci. 2019;161:1-27. doi: 
10.1016/bs.pmbts.2018.10.002 pmid: 30711023 
132. Mayer AK, Van Cauwenbergh C, Rother C, Baumann B, 
Reuter P, De Baere E, et al. CNGB3 mutation spectrum including 
copy number variations in 552 achromatopsia patients. Hum 
Mutat. 2017;38(11):1579-91. doi: 10.1002/humu.23311 pmid: 
28795510 
133. Pascual-Camps I, Barranco-Gonzalez H, Avino-Martinez J, 
Silva E, Harto-Castano M. Diagnosis and Treatment Options for 
Achromatopsia: A Review of the Literature. J Pediatr Ophthalmol 
Strabismus. 2018;55(2):85-92. doi: 10.3928/01913913-20171117-
01 pmid: 29257187 
134. Li S, Huang L, Xiao X, Jia X, Guo X, Zhang Q. Identification of 
CNGA3 mutations in 46 families: common cause of achromatopsia 
and cone-rod dystrophies in Chinese patients. JAMA Ophthalmol. 
2014;132(9):1076-83. doi: 10.1001/jamaophthalmol.2014.1032 
pmid: 24903488 
135. Guo LY, Zheng SL, Li J, Zhu Q, Duan WH, Zhang Y, et al. 
Phenotypic variability of SLC7A14 mutations in patients with 
inherited retinal dystrophy. Ophthalmic Genet. 2019;40(2):118-
23. doi: 10.1080/13816810.2019.1586964 pmid: 30924391 
136. Sugahara M, Oishi M, Oishi A, Ogino K, Morooka S, Gotoh 
N, et al. Screening for SLC7A14 gene mutations in patients with 
autosomal recessive or sporadic retinitis pigmentosa Ophthalmic 
Genet. 2017;38(1):70-3. doi: 10.3109/13816810.2015.1136336 
pmid: 27028480 
137. Jinda W, Poungvarin N, Taylor TD, Suzuki Y, 
Thongnoppakhun W, Limwongse C, et al. A novel start codon 
mutation of the MERTK gene in a patient with retinitis 
pigmentosa. Mol Vis. 2016;22:342-51. pmid: 27122965 
138. Audo I, Mohand-Said S, Boulanger-Scemama E, Zanlonghi X, 
Condroyer C, Demontant V, et al. MERTK mutation update in 
inherited retinal diseases. Hum Mutat. 2018;39(7):887-913. doi: 
10.1002/humu.23431 pmid: 29659094 
139. Liu S, Bi JG, Hu Y, Tang D, Li B, Zhu P, et al. Targeted next 
generation sequencing identified novel loss-of-function mutations 
in MERTK gene in Chinese patients with retinitis pigmentosa. Mol 
Genet Genomic Med. 2019;7(4):e00577. doi: 10.1002/mgg3.577 
pmid: 30790467
 
  
